CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Quinn T Ostrom; Haley Gittleman; Paul Farah; Annie Ondracek; Yanwen Chen; Yingli Wolinsky; Nancy E Stroup; Carol Kruchko; Jill S Barnholtz-Sloan

doi:10.1093/neuonc/not151

. 2013 Nov;15(Suppl 2):ii1–ii56. doi: 10.1093/neuonc/not151

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Quinn T Ostrom ¹, Haley Gittleman ¹, Paul Farah ¹, Annie Ondracek ¹, Yanwen Chen ¹, Yingli Wolinsky ¹, Nancy E Stroup ¹, Carol Kruchko ¹, Jill S Barnholtz-Sloan ¹

PMCID: PMC3798196 PMID: 24137015

Introduction

The objective of CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010 is to provide a current comprehensive review of the descriptive epidemiology of primary brain and central nervous system (CNS) tumors in the United States population. The Central Brain Tumor Registry of the United States (CBTRUS) obtained data on all newly diagnosed primary brain and CNS tumors from the Centers for Disease Control and Prevention (CDC), National Program of Cancer Registries (NPCR) and the National Cancer Institute (NCI), Surveillance, Epidemiology and End Results (SEER) program for diagnosis years 2006-2010. Incidence counts and rates of primary malignant and non-malignant brain and CNS tumors are documented by histology, gender, age, race, and Hispanic ethnicity. Mortality and relative survival rates for selected malignant histologies calculated using SEER data for the period 1995-2010 are also presented.

Background

The Central Brain Tumor Registry of the United States (CBTRUS) is a unique professional research organization that focuses exclusively on providing quality statistical data on population-based primary brain and CNS incident tumors in the United States. CBTRUS was incorporated as a nonprofit 501 (c) 3 with a founding and sustaining grant from the Pediatric Brain Tumor Foundation in 1992 following a two-year study conducted by the American Brain Tumor Association to determine the feasibility of a central registry for all primary brain and CNS tumor cases in the United States. Until that time, standard data reporting in the United States had been limited to malignant cases only.

CBTRUS is currently the only population-based site-specific registry in the United States that works in partnership with a public cancer surveillance organization, the NPCR (www.cdc.gov/cancer/npcr) of the CDC and from which data are directly received under a special agreement. This agreement permits transfer of data through the National Program of Cancer Registries Cancer Surveillance System (NPCR-CSS) Submission Specifications mechanism¹, the system utilized for collection of central (state) cancer data as mandated in 1992 by Public Law 102-515, the Cancer Registries Amendment Act.² Passed in 2002, the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107-260)³ expanded the collection of cancer by NPCR to include primary non-malignant brain and CNS tumors having International Classification of Diseases for Oncology Third Edition (ICD-O-3)⁴ codes beginning with the 2004 diagnosis year. All central cancer registries now include these data in their cancer collection practices and send them to NPCR. The passage of Public Law 107-260 paved the way for CBTRUS to access brain and CNS data through NPCR. CBTRUS researchers combine the NPCR data with data from the SEER (www.seer.cancer.gov) program⁵ of the NCI which was established for national cancer surveillance in the early 1970s. All data from NPCR and from SEER originate from tumor registrars who adhere to the Uniform Data Standards (UDS) for malignant and non-malignant brain and CNS tumors as directed by the North American Association of Cancer Registries (NAACCR) (www.naaccr.org). Along with the UDS, there are quality control checks and a system for rating each central registry to further insure that these data are reported as accurately and completely as possible. As a surveillance partner, CBTRUS can, therefore, report high quality data on brain and CNS tumors with histological specificity useful to the communities it serves. Its database contains the largest aggregation of population-based data on the incidence of all primary brain and CNS tumors in the United States.

This sixteenth statistical report, and second one published as a supplement to Neuro-Oncology, the official journal of the Society for Neuro-Oncology (www.soc-neuro-onc.org), continues the past efforts that CBTRUS has made to provide population-based incidence rates for all primary brain and CNS tumors by histology, age, gender, race, and Hispanic ethnicity. These data have been organized by clinically relevant histology groupings which were revised in 2012 in collaboration with three neuropathologists, Drs. Janet Bruner (University of Texas M.D. Anderson Medical Center), Roger McLendon (Duke University), and Tarik Tihan (University of California at San Francisco) to reflect the 2007 WHO Classification of Tumours of the Central Nervous System.⁶ These data provide information important for allocation and planning of specialty healthcare services, in the planning of disease prevention and control programs, in research activities and may lead to clues that will stimulate research into the causes of this terrible disease.

Technical Notes

Data Collection

CBTRUS does not collect data directly from patients' medical records. As noted, data for CBTRUS analyses come from the NPCR and SEER programs. By law, cancer and benign brain tumors are reportable diseases and tumor registrars in treatment centers send these data and other pertinent information to central cancer registries in their states where they are collated and sent to NPCR and SEER. On an annual basis, NPCR secures permission from the central cancer registries to release their data on brain and CNS tumors to CBTRUS. Central cancer registries play an essential role in the collection process, diagrammatically presented in Figure 1. These data are population-based and, therefore, represent by definition a comprehensive documentation of all cancers diagnosed within a region over a period of time.

Fig. 1. — Schematic of Cancer Registration Process

CBTRUS obtained incidence data from 50 cancer registries (45 NPCR and 5 SEER) that include cases of malignant and non-malignant (benign and uncertain) primary brain and CNS tumors. The 50 population-based cancer registries include 49 state registries (excluding Minnesota, as this registry did not provide data to NPCR in 2013) and the District of Columbia. It should be noted that metastatic tumors including those found in the brain and CNS are not collected by surveillance organization in the United States. Data were requested for all newly-diagnosed primary malignant and non-malignant tumors from 2006 to 2010 at any of the following anatomic sites (ICD-O-3 topography codes in parentheses): brain (C71.0-C71.9), meninges (C70.0-C70.9), spinal cord, cranial nerves, and other parts of the central nervous system (C72.0-C72.9), pituitary and pineal glands (C75.1-C75.3), and olfactory tumors of the nasal cavity [C30.0 (ICD-O-3 histology codes 9522 and 9523)].⁴

NPCR provided data on 313,780 primary brain and CNS tumors diagnosed from 2006 to 2010. NPCR cancer registries agree to participate in the CBTRUS Statistical Report and to pass certain data quality standards required by NPCR, thus allowing CBTRUS to receive and analyze the data. An additional 12,991 primary brain and CNS tumor case records for the time period were obtained from SEER. These data were combined into a single data set for analyses. A total of 8,175 records (2.4%) were deleted from the final analytic data set because of one or more of the following reasons: invalid site/histology combinations, duplicate records that included a less accurate reporting source than microscopic confirmation (e.g. radiographic versus microscopic confirmation), duplicate records for bilateral vestibular schwannoma or meningioma, duplicate record for recurrent disease, and errors in time sequence of diagnosis. The final analytic data set included 326,711 records from 50 population-based central cancer registries, including 49 state registries and the District of Columbia.

Survival data for malignant brain and CNS tumors were obtained from 18 SEER registries for years 1995 to 2010. Survival information derived from active patient follow-up is not available in the data that CBTRUS receives from NPCR registries, so this alternate data source is used for the generation of these tables. This dataset includes information from 9 state registries, 5 regional registries and the Alaska Native Tumor Registry. Together, this provides population-based information for about 26% of the United States Population.⁷ Survival was not calculated for non-malignant tumors as collection of these cases has only been mandated since 2004, and, therefore, not enough time has elapsed to accurately calculate relative survival.

Mortality data used in this report are from the National Center for Health Statistics (NCHS) and includes deaths where primary brain or CNS tumor was listed as cause of death on the death certificate for all 50 states and the District of Columbia.

Definitions

Measures in Surveillance Epidemiology

The Incidence Rate is a basic measure of disease occurrence that measures the occurrence count of newly-diagnosed cases of disease per 100,000 population over a time period. Mortality Rates quantify the number of people who have died from the disease per 100,000 population in a specific time period. Prevalence Rates measure the number of people with a disease per 100,000 population at a particular point in time or during a particular period of time. Survival Rates represent the percentage of individuals who survive their disease to a specified time period. Relative Survival Rates are defined as the observed probability of survival adjusted for the expected survival rate of the United States population for that age, gender, and calendar year.

Incidence and mortality rates in this report are expressed per unit population in which the events are observed. For cancer, rates are usually expressed per 100,000 population. The unadjusted rate of disease in an entire population is the Crude Rate. Crude rates are generally adjusted by age because as a population ages the crude rate would increase, and this may only reflect the aging of the population rather than an actual rate increase. Age-Adjusted Rates to a common standard population allow for comparisons of rates in populations across regions with different age structures. Incidence and mortality rates in this report are age-adjusted to the Year 2000 U.S. Standard Population. Rates for a subset of a population are termed specific rates. Specific rates by gender, race, and Hispanic ethnicity are also reported. The variability around the estimates of rates is reflected in the Standard Error, which is incorporated into the formula for computing the confidence interval associated with a certain rate. A Confidence Interval is the computed interval with a given probability (e.g., 95 percent) that the true value of a variable such as a mean, proportion, or rate occurs within the interval. For example, the age-adjusted primary brain and CNS tumor incidence rate is 21.03 cases per 100,000. We can assume with 95 percent certainty that the actual incidence rate is within the range of 20.96 and 21.11 cases per 100,000. Incidence Rate Ratio is calculated to compare incidence rates between selected populations, and is generated by dividing the incidence rate of one group by the incidence rate of the comparison group. For example, for the age-adjusted incidence rate of glioblastoma is 3.97 case per 100,000 for males and 2.53 cases per 100,000 for females. This results in an incidence rate ratio of 1.57, meaning that men have an incidence rate of glioblastoma that is 1.57 times the rate of women.

Comparing incidence rates between statistical reports produced by multiple reporting organizations is not recommended. To compare incidence rates for brain and CNS tumors among statistical reports, agencies, or registries, a number of factors should be considered. These factors include whether the case definition, data collection, and rate calculation are similar between comparison sources. The following questions may be helpful in determining the comparability of reporting sources:

How is an incident case determined and defined?
Does the data set include both malignant and non-malignant tumors?
What anatomic locations (primary sites) are included?
Are lymphomas and hematopoietic neoplasms included in the incidence rates?
Are the populations comparable by time period, geography, and age distribution?
Are the incidence rates age-adjusted? If so, to which standard population are they age-adjusted?

Classification by Behavior and Histology

Brain and CNS tumor classifications according to behavior ICD-O-3 standards for benign, uncertain, and malignant behaviors are coded 0, 1, and 3, respectively. The histology groupings in CBTRUS statistical reports were initially developed in collaboration with the CBTRUS consulting neuropathologist, Dr. Janet Bruner of the University of Texas M.D. Anderson Cancer Center. In 2012, Drs. Roger McLendon and Tarik Tihan joined Dr. Bruner and CBTRUS staff to synchronize CBTRUS histology grouping scheme with the 2007 World Health Organization (WHO) classification of tumors of the central nervous system.^6,8 This report uses the most recent 2012 CBTRUS Histology Grouping Scheme (Table 1). The classification scheme utilizes ICD-O-3 codes⁴ and may include morphology codes that were not previously reported to CBTRUS.⁹ Tables 1a and 1b list malignant only and non-malignant only histologies, respectively. In this report, incidence rates are provided by major histology grouping and detailed histology.

Table 1.

Central Brain Tumor Registry of the United States (CBTRUS), Brain and Central Nervous System Tumor Histology Groupings^∥

Histology	ICD-O-3^† Histology Code
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma	9421
Diffuse astrocytoma	9400, 9410, 9411, 9420
Anaplastic astrocytoma	9401
Unique astrocytoma variants	9381, 9384, 9424
Glioblastoma	9440, 9441, 9442/3^‡
Oligodendroglioma	9450
Anaplastic oligodendroglioma	9451, 9460
Oligoastrocytic tumors	9382
Ependymal tumors	9383, 9391, 9392, 9393, 9394
Glioma malignant, NOS	9380
Choroid plexus tumors	9390
Other neuroepithelial tumors	9363, 9423, 9430, 9444
Neuronal and mixed neuronal-glial tumors	8680, 8681, 8690, 8693, 9412, 9413, 9442/1^§,
	9492 (excluding site C75.1), 9493, 9505, 9506, 9522, 9523
Tumors of the pineal region	9360, 9361, 9362
Embryonal tumors	8963, 9364, 9470, 9471, 9472, 9473, 9474, 9480,
	9490, 9500, 9501, 9502, 9508
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors	9540, 9541, 9550, 9560, 9561, 9570, 9571
Other tumors of cranial and spinal nerves	9562
Tumors of Meninges
Meningioma	9530, 9531, 9532, 9533, 9534, 9537, 9538, 9539
Mesenchymal tumors	8324, 8800, 8801, 8802, 8803, 8804, 8805, 8806, 8810, 8815, 8824, 8830,
	8831, 8835, 8836, 8850, 8851, 8852, 8853, 8854, 8857, 8861, 8870, 8880,
	8890, 8897, 8900, 8901, 8902, 8910, 8912, 8920, 8921, 8935, 8990, 9040, 9136,
	9150, 9170, 9180, 9210, 9241, 9260, 9373,
Primary melanocytic lesions	8720, 8728, 8770, 8771
Other neoplasms related to the meninges	9161, 9220, 9231, 9240, 9243, 9370, 9371, 9372, 9535
Lymphomas and Hemopoietic Neoplasms
Lymphoma	9590, 9591, 9596, 9650, 9651, 9652, 9653, 9654, 9655, 9659, 9661,
	9662, 9663, 9664, 9665, 9667, 9670, 9671, 9673, 9675, 9680, 9684,
	9687, 9690, 9691, 9695, 9698, 9699, 9701, 9702, 9705, 9714, 9719,
	9728, 9729
Other hemopoietic neoplasms	9727, 9731, 9733, 9734, 9740, 9741, 9750, 9751, 9752, 9753, 9754, 9755,
	9756, 9757, 9758, 9760, 9766, 9823, 9826, 9827, 9832, 9837, 9860, 9861, 9866, 9930, 9970
Germ Cell Tumors and Cysts
Germ cell tumors, cysts and heterotopias	8020, 8440, 9060, 9061, 9064, 9065, 9070, 9071, 9072, 9080, 9081, 9082,
	9083, 9084, 9085, 9100, 9101
Tumors of Sellar Region
Tumors of the pituitary	8040, 8140, 8146, 8246, 8260, 8270, 8271, 8272,
	8280, 8281, 8290, 8300, 8310, 8323, 9492 (Site C75.1 only), 9582
Craniopharyngioma	9350, 9351, 9352
Unclassified Tumors
Hemangioma	9120, 9121, 9122, 9123, 9125, 9130, 9131, 9133, 9140
Neoplasm, unspecified	8000, 8001, 8002, 8003, 8004, 8005, 8010, 8021
All other	8320, 8452, 8710, 8711, 8713, 8811, 8840, 8896, 8980, 9173, 9503, 9580

Histology	ICD-O-3^‡ Histology Code
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma	9421/1 [Included with malignant tumors as explained in Brain Tumor Definition Differences]
Diffuse astrocytoma	9400/3, 9410/3, 9411/3, 9420/3
Anaplastic astrocytoma	9401/3
Unique astrocytoma variants	9381/3, 9424/3
Glioblastoma	9440/3, 9441/3, 9442/3
Oligodendroglioma	9450/3
Anaplastic oligodendroglioma	9451/3, 9460/3
Oligoastrocytic tumors	9382/3
Ependymal tumors	9391/3, 9392/3, 9393/3
Glioma malignant, NOS	9380/3
Choroid plexus	9390/3
Other neuroepithelial tumors	9423/3, 9430/3
Neuronal and mixed neuronal- glial tumors	8680/3, 8693/3, 9505/3, 9522/3, 9523/3
Tumors of the pineal region	9362/3
Embryonal tumors	8963/3, 9364/3, 9470/3, 9471/3, 9472/3,9473/3, 9474/3, 9480/3,
	9490/3, 9500/3, 9501/3, 9502/3, 9508/3
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors	9540/3, 9560/3, 9561/3, 9571/3
Tumors of Meninges
Meningioma	9530/3, 9538/3, 9539/3
Mesenchymal tumors	8800/3, 8801/3, 8802/3, 8803/3, 8804/3, 8805/3, 8806/3, 8810/3, 8815/3, 8830/3,
	8850/3, 8851/3, 8852/3, 8853/3, 8854/3, 8857/3, 8890/3, 8900/3, 8901/3, 8902/3,
	8910/3, 8912/3, 8920/3, 8921/3, 8990/3, 9040/3, 9150/3, 9170/3, 9180/3, 9260/3
Primary melanocytic lesions	8720/3, 8728/3, 8770/3, 8771/3
Other neoplasms related to the meninges	9220/3, 9231/3, 9240/3, 9243/3, 9370/3, 9371/3, 9372/3
Lymphomas and Hemopoietic Neoplasms
Lymphoma	9590/3, 9591/3, 9596/3, 9650/3, 9651/3, 9652/3, 9653/3, 9654/3, 9655/3, 9659/3,
	9661/3, 9662/3, 9663/3, 9664/3, 9665/3, 9667/3, 9670/3, 9671/3, 9673/3, 9675/3,
	9680/3, 9684/3, 9687/3, 9690/3, 9691/3, 9695/3, 9698/3, 9699/3, 9701/3, 9702/3,
	9705/3, 9714/3, 9719/3, 9728/3, 9729/3
Other hemopoietic neoplasms	9727/3, 9731/3, 9733/3, 9734/3, 9740/3, 9741/3, 9750/3, 9754/3, 9755/3, 9756/3, 9757/3, 9758/3,
	9760/3, 9823/3, 9826/3, 9827/3, 9832/3, 9837/3, 9860/3, 9861/3, 9866/3, 9930/3
Germ Cell Tumors and Cysts
Germ cell tumors, cysts and	8020/3, 8440/3, 9060/3, 9061/3, 9064/3, 9065/3, 9070/3, 9071/3, 9072/3, 9080/3,
heterotopias	9081/3, 9082/3, 9083/3, 9084/3, 9085/3, 9100/3, 9101/3
Tumors of Sellar Region
Tumors of the pituitary	8140/3, 8246/3, 8260/3, 8270/3, 8272/3, 8280/3, 8281/3, 8290/3, 8300/3, 8310/3, 8323/3
Unclassified Tumors
Hemangioma	9120/3, 9130/3, 9133/3, 9140/3
Neoplasm, unspecified	8000/3, 8001/3, 8002/3, 8003/3, 8004/3, 8005/3, 8010/3, 8021/3
All other	8320/3, 8710/3, 8711/3, 8811/3, 8840/3, 8896/3, 8980/3, 9503/3, 9580/3

Histology	Total			Male			Female
Histology	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI
Tumors of Neuroepithelial Tissue	101,825	6.60	(6.56-6.64)	56,695	7.76	(7.70-7.83)	45,130	5.60	(5.55-5.65)
Pilocytic astrocytoma	4,741	0.33	(0.32-0.34)	2,425	0.33	(0.32-0.35)	2,316	0.33	(0.31-0.34)
Diffuse astrocytoma	8,535	0.56	(0.55-0.58)	4,785	0.66	(0.64-0.68)	3,750	0.48	(0.47-0.50)
Anaplastic astrocytoma	5,621	0.37	(0.36-0.38)	3,169	0.43	(0.42-0.45)	2,452	0.31	(0.29-0.32)
Unique astrocytoma variants	943	0.06	(0.06-0.07)	515	0.07	(0.06-0.08)	428	0.06	(0.05-0.06)
Glioblastoma	50,872	3.19	(3.16-3.21)	29,019	3.97	(3.92-4.01)	21,853	2.53	(2.50-2.57)
Oligodendroglioma	4,020	0.27	(0.26-0.28)	2,218	0.30	(0.29-0.32)	1,802	0.24	(0.23-0.25)
Anaplastic oligodendroglioma	1,658	0.11	(0.10-0.11)	931	0.13	(0.12-0.13)	727	0.09	(0.09-0.10)
Oligoastrocytic tumors	3,045	0.20	(0.20-0.21)	1,734	0.24	(0.23-0.25)	1,311	0.17	(0.16-0.18)
Ependymal tumors	6,304	0.42	(0.41-0.43)	3,508	0.47	(0.46-0.49)	2,796	0.36	(0.35-0.38)
Glioma malignant, NOS	6,765	0.46	(0.44-0.47)	3,397	0.48	(0.46-0.50)	3,368	0.44	(0.42-0.45)
Choroid plexus tumors	797	0.05	(0.05-0.06)	374	0.05	(0.05-0.06)	423	0.06	(0.05-0.06)
Other neuroepithelial tumors	93	0.01	(0.01-0.01)	33	0.00	(0.00-0.01)	60	0.01	(0.01-0.01)
Neuronal and mixed neuronal-glial tumors	4,036	0.27	(0.26-0.28)	2,143	0.29	(0.28-0.30)	1,893	0.26	(0.24-0.27)
Tumors of the pineal region	605	0.04	(0.04-0.04)	237	0.03	(0.03-0.04)	368	0.05	(0.04-0.05)
Embryonal tumors	3,790	0.26	(0.26-0.27)	2,207	0.30	(0.29-0.32)	1,583	0.22	(0.21-0.23)
Tumors of Cranial and Spinal Nerves	26,564	1.69	(1.67-1.71)	12,671	1.69	(1.66-1.72)	13,893	1.70	(1.67-1.73)
Nerve sheath tumors	26,548	1.69	(1.67-1.71)	12,664	1.69	(1.66-1.72)	13,884	1.70	(1.67-1.72)
Other tumors of cranial and spinal nerves	16	0.00	(0.00-0.00)	–	–	–	–	–	–
Tumors of Meninges	121,110	7.71	(7.67-7.75)	33,090	4.73	(4.68-4.79)	88,020	10.27	(10.20-10.34)
Meningioma	116,986	7.44	(7.40-7.48)	30,888	4.44	(4.39-4.49)	86,098	10.02	(9.96-10.09)
Mesenchymal tumors	1,229	0.08	(0.08-0.09)	584	0.08	(0.07-0.09)	645	0.08	(0.08-0.09)
Primary melanocytic lesions	116	0.01	(0.01-0.01)	70	0.01	(0.01-0.01)	46	0.01	(0.00-0.01)
Other neoplasms related to the meninges	2,779	0.18	(0.17-0.19)	1,548	0.21	(0.20-0.22)	1,231	0.16	(0.15-0.17)
Lymphomas and Hemopoietic Neoplasms	7,122	0.46	(0.45-0.47)	3,751	0.52	(0.51-0.54)	3,371	0.40	(0.39-0.41)
Lymphoma	6,919	0.44	(0.43-0.46)	3,648	0.51	(0.49-0.53)	3,271	0.39	(0.37-0.40)
Other hemopoietic neoplasms	203	0.01	(0.01-0.02)	103	0.01	(0.01-0.02)	100	0.01	(0.01-0.02)
Germ Cell Tumors and Cysts	1,464	0.10	(0.10-0.11)	1,005	0.14	(0.13-0.14)	459	0.06	(0.06-0.07)
Germ cell tumors, cysts and heterotopias	1,464	0.10	(0.10-0.11)	1,005	0.14	(0.13-0.14)	459	0.06	(0.06-0.07)
Tumors of Sellar Region	50,709	3.32	(3.29-3.34)	22,795	3.11	(3.07-3.15)	27,914	3.60	(3.55-3.64)
Tumors of the pituitary	47,958	3.13	(3.10-3.16)	21,482	2.93	(2.89-2.97)	26,476	3.41	(3.37-3.45)
Craniopharyngioma	2,751	0.18	(0.18-0.19)	1,313	0.18	(0.17-0.19)	1,438	0.19	(0.18-0.20)
Unclassified Tumors	17,917	1.16	(1.14-1.18)	7,954	1.16	(1.13-1.18)	9,963	1.17	(1.14-1.19)
Hemangioma	3,934	0.26	(0.25-0.27)	1,724	0.24	(0.22-0.25)	2,210	0.28	(0.27-0.29)
Neoplasm, unspecified	13,895	0.90	(0.88-0.91)	6,188	0.92	(0.89-0.94)	7,707	0.88	(0.86-0.90)
All other	88	0.01	(0.00-0.01)	42	0.01	(0.00-0.01)	46	0.01	(0.00-0.01)
TOTAL^‡	326,711	21.03	(20.96-21.11)	137,961	19.11	(19.00-19.21)	188,750	22.79	(22.68-22.89)

	Age At Diagnosis
	0-4			5-9			10-14			15-19			0-19^‡			0-14^‡
	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI
Tumors of Neuroepithelial Tissue	4,750	4.8	(4.66-4.93)	3,723	3.79	(3.67-3.91)	3,215	3.15	(3.04-3.26)	2,908	2.68	(2.58-2.78)	14,596	3.59	(3.53-3.65)	11,688	3.9	(3.82-3.97)
Pilocytic astrocytoma	951	0.96	(0.90-1.03)	898	0.91	(0.85-0.97)	846	0.83	(0.77-0.89)	633	0.58	(0.54-0.63)	3,328	0.82	(0.79-0.85)	2,695	0.90	(0.87-0.93)
Diffuse astrocytoma	338	0.34	(0.31-0.38)	233	0.24	(0.21-0.27)	266	0.26	(0.23-0.29)	278	0.26	(0.23-0.29)	1,115	0.27	(0.26-0.29)	837	0.28	(0.26-0.30)
Anaplastic astrocytoma	66	0.07	(0.05-0.09)	90	0.09	(0.07-0.11)	92	0.09	(0.07-0.11)	105	0.10	(0.08-0.12)	353	0.09	(0.08-0.10)	248	0.08	(0.07-0.09)
Unique astrocytoma variants	69	0.07	(0.05-0.09)	89	0.09	(0.07-0.11)	130	0.13	(0.11-0.15)	127	0.12	(0.10-0.14)	415	0.10	(0.09-0.11)	288	0.10	(0.09-0.11)
Glioblastoma	93	0.09	(0.08-0.12)	152	0.16	(0.13-0.18)	163	0.16	(0.14-0.19)	180	0.17	(0.14-0.19)	588	0.14	(0.13-0.16)	408	0.14	(0.12-0.15)
Oligodendroglioma	27	0.03	(0.02-0.04)	42	0.04	(0.03-0.06)	55	0.05	(0.04-0.07)	107	0.10	(0.08-0.12)	231	0.06	(0.05-0.06)	124	0.04	(0.03-0.05)
Anaplastic oligodendroglioma	–	–	–	–	–	–	–	–	–	25	0.02	(0.01-0.03)	44	0.01	(0.01-0.01)	19	0.01	(0.00-0.01)
Oligoastrocytic tumors	31	0.03	(0.02-0.04)	27	0.03	(0.02-0.04)	36	0.04	(0.02-0.05)	50	0.05	(0.03-0.06)	144	0.04	(0.03-0.04)	94	0.03	(0.03-0.04)
Ependymal tumors	430	0.43	(0.39-0.48)	215	0.22	(0.19-0.25)	212	0.21	(0.18-0.24)	275	0.25	(0.22-0.29)	1,132	0.28	(0.26-0.29)	857	0.28	(0.26-0.30)
Glioma malignant, NOS	887	0.90	(0.84-0.96)	848	0.86	(0.80-0.92)	455	0.45	(0.41-0.49)	287	0.26	(0.23-0.30)	2,477	0.61	(0.59-0.64)	2,190	0.73	(0.70-0.76)
Choroid plexus tumors	275	0.28	(0.24-0.31)	43	0.04	(0.03-0.06)	39	0.04	(0.03-0.05)	50	0.05	(0.03-0.06)	407	0.10	(0.09-0.11)	357	0.12	(0.10-0.13)
Other neuroepithelial tumors	–	–	–	–	–	–	–	–	–	–	–	–	31	0.01	(0.01-0.01)	26	0.01	(0.01-0.01)
Neuronal and mixed neuronal-glial tumors	256	0.26	(0.23-0.29)	305	0.31	(0.28-0.35)	435	0.42	(0.39-0.47)	482	0.44	(0.41-0.49)	1,478	0.36	(0.34-0.38)	996	0.33	(0.31-0.35)
Tumors of the pineal region	57	0.06	(0.04-0.07)	36	0.04	(0.03-0.05)	35	0.03	(0.02-0.05)	44	0.04	(0.03-0.05)	172	0.04	(0.04-0.05)	128	0.04	(0.04-0.05)
Embryonal tumors	1,263	1.27	(1.20-1.35)	736	0.75	(0.70-0.80)	422	0.41	(0.38-0.46)	260	0.24	(0.21-0.27)	2,681	0.66	(0.64-0.69)	2,421	0.8	(0.77-0.84)
Tumors of Cranial and Spinal Nerves	287	0.29	(0.26-0.32)	226	0.23	(0.20-0.26)	224	0.22	(0.19-0.25)	357	0.33	(0.30-0.37)	1,094	0.27	(0.25-0.28)	737	0.25	(0.23-0.26)
Nerve sheath tumors	287	0.29	(0.26-0.32)	226	0.23	(0.20-0.26)	224	0.22	(0.19-0.25)	357	0.33	(0.3-0.37)	1,094	0.27	(0.25-0.28)	737	0.25	(0.23-0.26)
Other tumors of cranial and spinal nerves	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Tumors of Meninges	124	0.12	(0.10-0.15)	94	0.10	(0.08-0.12)	209	0.2	(0.18-0.23)	410	0.38	(0.34-0.42)	837	0.20	(0.19-0.22)	427	0.14	(0.13-0.16)
Meningioma	56	0.06	(0.04-0.07)	53	0.05	(0.04-0.07)	149	0.14	(0.12-0.17)	272	0.25	(0.22-0.28)	530	0.13	(0.12-0.14)	258	0.09	(0.08-0.10)
Mesenchymal tumors	56	0.06	(0.04-0.07)	32	0.03	(0.02-0.05)	30	0.03	(0.02-0.04)	38	0.03	(0.02-0.05)	156	0.04	(0.03-0.04)	118	0.04	(0.03-0.05)
Primary melanocytic lesions	–	–	–	–	–	–	–	–	–	–	–	–	16	0.00	(0.00-0.01)	–	–	–
Other neoplasms related to the meninges	–	–	–	–	–	–	28	0.03	(0.02-0.04)	95	0.09	(0.07-0.11)	135	0.03	(0.03-0.04)	40	0.01	(0.01-0.02)
Lymphomas and Hemopoietic Neoplasms	21	0.02	(0.01-0.03)	27	0.03	(0.02-0.04)	19	0.02	(0.01-0.03)	34	0.03	(0.02-0.04)	101	0.02	(0.02-0.03)	67	0.02	(0.02-0.03)
Lymphoma	–	–	–	16	0.02	(0.01-0.03)	–	–	–	22	0.02	(0.01-0.03)	58	0.01	(0.01-0.02)	36	0.01	(0.01-0.02)
Other hemopoietic neoplasms	–	–	–	–	–	–	–	–	–	–	–	–	43	0.01	(0.01-0.01)	31	0.01	(0.01-0.01)
Germ Cell Tumors and Cysts	122	0.12	(0.10-0.15)	148	0.15	(0.13-0.18)	295	0.29	(0.26-0.33)	301	0.28	(0.25-0.31)	866	0.21	(0.2-0.23)	565	0.19	(0.17-0.21)
Germ cell tumors, cysts and heterotopias	122	0.12	(0.10-0.15)	148	0.15	(0.13-0.18)	295	0.29	(0.26-0.33)	301	0.28	(0.25-0.31)	866	0.21	(0.20-0.23)	565	0.19	(0.17-0.21)
Tumors of Sellar Region	178	0.18	(0.15-0.21)	385	0.39	(0.36-0.44)	638	0.62	(0.57-0.67)	1,673	1.54	(1.47-1.62)	2,874	0.69	(0.66-0.71)	1,201	0.4	(0.38-0.43)
Tumors of the pituitary	36	0.04	(0.03-0.05)	116	0.12	(0.1-0.14)	427	0.41	(0.37-0.45)	1,509	1.39	(1.32-1.46)	2,088	0.49	(0.47-0.52)	579	0.19	(0.18-0.21)
Craniopharyngioma	142	0.14	(0.12-0.17)	269	0.27	(0.24-0.31)	211	0.21	(0.18-0.24)	164	0.15	(0.13-0.18)	786	0.20	(0.18-0.21)	622	0.21	(0.19-0.23)
Unclassified Tumors	238	0.24	(0.21-0.27)	192	0.20	(0.17-0.23)	283	0.28	(0.25-0.31)	431	0.4	(0.36-0.44)	1,144	0.28	(0.26-0.29)	713	0.24	(0.22-0.26)
Hemangioma	52	0.05	(0.04-0.07)	52	0.05	(0.04-0.07)	96	0.09	(0.08-0.11)	158	0.15	(0.12-0.17)	358	0.09	(0.08-0.10)	200	0.07	(0.06-0.08)
Neoplasm, unspecified	183	0.18	(0.16-0.21)	139	0.14	(0.12-0.17)	184	0.18	(0.16-0.21)	270	0.25	(0.22-0.28)	776	0.19	(0.18-0.20)	506	0.17	(0.15-0.18)
All other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
TOTAL^§	5,720	5.77	(5.63-5.93)	4,795	4.89	(4.75-5.03)	4,883	4.78	(4.64-4.91)	6,114	5.64	(5.5-5.78)	21,512	5.26	(5.19-5.33)	15,398	5.14	(5.05-5.22)

State	No. Of Newly Diagnosed Tumors	Percent Non-Malignant Tumors	Histologically Confirmed Percent	Radiographically Confirmed Percent	Average Annual 2006-2010 Population^†
Alabama	4,187	56.8	72.4	23.8	4,712,673
Alaska	697	65.1	61.5	35.6	691,220
Arizona	6,647	64.7	63.2	30.9	6,246,699
Arkansas	3,001	63.7	59.5	35.4	2,872,679
California	35,034	65.4	67.9	28.8	36,635,055
Colorado	6,285	72.1	53.3	43.7	4,886,782
Connecticut	3,663	60.2	70.4	27.5	3,545,523
Delaware	913	61.8	68.8	27.7	881,283
District of Columbia	543	63.5	66.3	28.4	584,492
Florida	24,121	68.6	60.2	36.7	18,510,679
Georgia	9,437	66.9	61.7	35.1	9,468,729
Hawaii	1,317	73.0	59.4	37.1	1,333,539
Idaho	1,466	61.3	67.9	27.6	1,526,727
Illinois	14,205	66.9	59.9	37.8	12,745,123
Indiana	6,848	63.2	57.7	39.8	6,417,404
Iowa	3,486	63.2	62.6	35.1	3,016,332
Kansas	2,756	62.2	62.9	32.9	2,809,328
Kentucky	5,769	68.9	53.3	43.1	4,286,017
Louisiana	4,450	67.2	65.3	31.3	4,430,165
Maine	1,344	53.2	75.2	21.2	1,327,627
Maryland	5,558	63.9	67.7	26.7	5,696,362
Massachusetts	6,580	58.8	73.9	22.5	6,476,738
Michigan	11,306	64.7	62.7	33.2	9,952,598
Mississippi	2,875	65.3	63.1	32.7	2,941,996
Missouri	6,934	66.3	59.9	36.1	5,922,207
Montana	1,150	66.2	63.0	33.3	973,751
Nebraska	1,783	59.7	68.5	28.1	1,799,067
Nevada	2,097	60.6	72.7	21.9	2,633,262
New Hampshire	1,397	58.8	72.8	24.4	1,313,949
New Jersey	9,263	61.5	67.9	27.8	8,721,170
New Mexico	1,758	63.6	71.8	22.2	2,013,117
New York	24,074	69.1	60.6	36.7	19,230,335
North Carolina	10,096	66.0	68.4	28.5	9,270,911
North Dakota	543	58.9	61.1	33.9	659,882
Ohio	10,861	57.7	68.9	25.4	11,512,787
Oklahoma	3,382	57.6	63.1	33.5	3,675,034
Oregon	4,041	60.3	72.5	25.4	3,761,796
Pennsylvania	16,288	66.1	60.8	34.0	12,614,322
Rhode Island	1,138	66.2	70.0	27.8	1,056,318
South Carolina	4,766	64.4	61.6	32.2	4,511,586
South Dakota	735	61.6	63.1	32.2	799,489
Tennessee	7,622	68.0	58.1	38.8	6,235,072
Texas	26,859	69.6	55.4	38.6	24,311,166
Utah	2,707	67.6	70.2	29.0	2,657,036
Vermont	922	66.2	60.6	37.5	624,250
Virginia	7,509	64.1	68.0	28.9	7,841,622
Washington	8,837	70.1	56.6	40.1	6,560,989
West Virginia	2,097	61.8	61.4	35.2	1,840,883
Wisconsin	6,801	63.1	58.9	36.8	5,638,070
Wyoming	563	60.9	71.2	28.2	545,598
TOTAL	326,711	65.6	62.9	33.3	298,719,439

State	0-19 Years				20+ Years				All Ages
State	Malignant		Non-Malignant		Malignant		Non-Malignant		Malignant		Non-Malignant		All Tumors
	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
Alabama	3.15	(2.73-3.62)	0.93	(0.71-1.20)	8.87	(8.43-9.32)	12.87	(12.35-13.42)	7.23	(6.89-7.57)	9.45	(9.07, 9.84)	16.67	(16.17-17.19)
Alaska	3.00	(2.04-4.26)	3.08	(2.12-4.33)	9.95	(8.55-11.50)	19.77	(17.77-21.92)	7.96	(6.92-9.10)	14.98	(13.53-16.54)	22.94	(21.13-24.85)
Arizona	3.19	(2.83-3.58)	1.71	(1.45-2.01)	8.89	(8.50-9.28)	18.07	(17.52-18.64)	7.25	(6.96-7.56)	13.38	(12.98-13.79)	20.63	(20.14-21.14)
Arkansas	3.49	(2.93-4.12)	3.43	(2.87-4.05)	8.55	(8.00-9.12)	16.22	(15.47-17.01)	7.10	(6.67-7.54)	12.55	(11.99-13.14)	19.65	(18.94-20.37)
California	2.98	(2.84-3.13)	1.66	(1.55-1.77)	8.30	(8.14-8.46)	17.33	(17.10-17.56)	6.78	(6.66-6.90)	12.83	(12.67-13.00)	19.61	(19.40-19.82)
Colorado	2.84	(2.45-3.27)	1.97	(1.65-2.34)	9.13	(8.67-9.60)	26.04	(25.26-26.83)	7.32	(6.98-7.68)	19.13	(18.57-19.71)	26.46	(25.79-27.13)
Connecticut	3.47	(2.95-4.05)	1.55	(1.21-1.95)	9.30	(8.79-9.83)	15.27	(14.61-15.94)	7.63	(7.23-8.03)	11.33	(10.85-11.82)	18.96	(18.34-19.59)
Delaware	3.82	(2.77-5.13)	2.32	(1.53-3.38)	9.00	(8.01-10.09)	15.50	(14.20-16.89)	7.52	(6.74-8.36)	11.72	(10.76-12.75)	19.24	(17.99-20.55)
District of Columbia	3.43	(2.08-5.32)	2.66	(1.51-4.34)	8.41	(7.20-9.77)	15.39	(13.74-17.18)	6.98	(6.02-8.06)	11.74	(10.50-13.08)	18.72	(17.14-20.41)
Florida	3.55	(3.30-3.80)	2.09	(1.90-2.28)	8.64	(8.43-8.86)	20.44	(20.12-20.77)	7.18	(7.02-7.35)	15.18	(14.94-15.42)	22.36	(22.07-22.65)
Georgia	3.40	(3.10-3.73)	1.67	(1.46-1.90)	8.33	(8.01-8.66)	18.97	(18.49-19.47)	6.92	(6.67-7.17)	14.01	(13.66-14.37)	20.93	(20.50-21.36)
Hawaii	2.73	(2.00-3.65)	1.24	(0.77-1.90)	5.96	(5.30-6.67)	18.12	(16.96-19.33)	5.03	(4.51-5.59)	13.28	(12.43-14.16)	18.31	(17.31-19.34)
Idaho	2.55	(1.94-3.28)	1.69	(1.20-2.31)	9.41	(8.60-10.28)	16.18	(15.10-17.32)	7.44	(6.83-8.09)	12.03	(11.24-12.85)	19.47	(18.47-20.51)
Illinois	3.00	(2.75-3.27)	2.01	(1.80-2.22)	8.94	(8.67-9.22)	19.58	(19.18-19.99)	7.24	(7.03-7.45)	14.54	(14.25-14.84)	21.78	(21.42-22.14)
Indiana	3.61	(3.23-4.02)	1.98	(1.70-2.29)	9.17	(8.78-9.56)	17.41	(16.87-17.95)	7.57	(7.28-7.88)	12.98	(12.59-13.38)	20.56	(20.07-21.05)
Iowa	3.41	(2.87-4.03)	1.74	(1.36-2.19)	9.57	(9.02-10.16)	17.89	(17.12-18.68)	7.81	(7.38-8.25)	13.25	(12.69-13.83)	21.06	(20.35-21.79)
Kansas	2.90	(2.40-3.48)	1.76	(1.38-2.23)	8.88	(8.31-9.48)	15.68	(14.92-16.47)	7.16	(6.73-7.62)	11.69	(11.13-12.26)	18.85	(18.15-19.58)
Kentucky	3.59	(3.11-4.11)	2.32	(1.94-2.75)	9.70	(9.22-10.19)	23.69	(22.94-24.46)	7.94	(7.58-8.32)	17.56	(17.01-18.12)	25.50	(24.84-26.18)
Louisiana	3.23	(2.80-3.71)	1.75	(1.43-2.11)	7.75	(7.32-8.20)	17.96	(17.30-18.64)	6.46	(6.12-6.80)	13.31	(12.83-13.80)	19.77	(19.18-20.36)
Maine	4.07	(3.13-5.22)	1.26	(0.77-1.94)	9.97	(9.15-10.85)	12.63	(11.69-13.64)	8.28	(7.63-8.98)	9.37	(8.68-10.10)	17.65	(16.69-18.65)
Maryland	2.97	(2.60-3.39)	1.55	(1.28-1.85)	8.47	(8.08-8.88)	16.36	(15.81-16.93)	6.89	(6.59-7.21)	12.11	(11.71-12.52)	19.01	(18.50-19.52)
Massachusetts	3.71	(3.30-4.16)	1.88	(1.60-2.20)	9.51	(9.13-9.90)	14.53	(14.06-15.01)	7.85	(7.55-8.15)	10.90	(10.55-11.25)	18.75	(18.29-19.21)
Michigan	3.64	(3.33-3.98)	1.90	(1.68-2.15)	9.14	(8.83-9.45)	18.52	(18.09-18.97)	7.56	(7.32-7.80)	13.75	(13.44-14.08)	21.32	(20.92-21.72)
Mississippi	2.72	(2.24-3.26)	1.73	(1.36-2.17)	8.17	(7.63-8.73)	16.96	(16.18-17.77)	6.60	(6.19-7.03)	12.59	(12.02-13.18)	19.19	(18.49-19.92)
Missouri	3.21	(2.83-3.63)	1.40	(1.16-1.68)	9.08	(8.69-9.48)	19.72	(19.14-20.32)	7.40	(7.10-7.71)	14.47	(14.04-14.90)	21.86	(21.34-22.39)
Montana	2.51	(1.70-3.56)	1.75	(1.11-2.63)	8.98	(8.05-9.98)	19.06	(17.67-20.53)	7.12	(6.41-7.89)	14.10	(13.09-15.17)	21.22	(19.98-22.52)
Nebraska	3.62	(2.92-4.44)	2.62	(2.03-3.33)	9.40	(8.67-10.18)	14.75	(13.83-15.70)	7.74	(7.18-8.34)	11.27	(10.59-11.98)	19.01	(18.12-19.92)
Nevada	2.23	(1.77-2.78)	0.61	(0.38-0.93)	7.81	(7.24-8.40)	13.48	(12.73-14.26)	6.21	(5.78-6.65)	9.79	(9.25-10.35)	15.99	(15.30-16.71)
New Hampshire	4.20	(3.25-5.34)	2.08	(1.46-2.88)	9.84	(8.99-10.75)	15.04	(13.98-16.15)	8.22	(7.55-8.94)	11.32	(10.54-12.14)	19.54	(18.51-20.62)
New Jersey	3.80	(3.45-4.17)	1.89	(1.65-2.16)	9.34	(9.01-9.68)	16.22	(15.79-16.66)	7.75	(7.49-8.01)	12.11	(11.79-12.43)	19.86	(19.45-20.27)
New Mexico	2.30	(1.78-2.93)	1.78	(1.33-2.35)	7.61	(6.99-8.28)	14.27	(13.41-15.17)	6.09	(5.62-6.59)	10.69	(10.06-11.34)	16.78	(15.99-17.60)
New York	3.64	(3.41-3.89)	2.39	(2.20-2.59)	8.87	(8.65-9.09)	21.69	(21.35-22.03)	7.37	(7.20-7.54)	16.15	(15.90-16.40)	23.52	(23.22-23.82)
North Carolina	3.25	(2.94-3.58)	1.89	(1.66-2.14)	8.72	(8.40-9.04)	18.67	(18.21-19.14)	7.15	(6.91-7.39)	13.86	(13.52-14.20)	21.00	(20.59-21.42)
North Dakota	3.07	(1.98-4.52)	0.79	(0.32-1.64)	7.45	(6.43-8.59)	12.29	(10.93-13.77)	6.20	(5.39-7.09)	8.99	(8.01-10.06)	15.19	(13.90-16.55)
Ohio	3.29	(3.01-3.59)	1.99	(1.78-2.22)	9.12	(8.84-9.41)	13.39	(13.04-13.74)	7.45	(7.23-7.67)	10.12	(9.86-10.37)	17.57	(17.23-17.90)
Oklahoma	2.82	(2.38-3.32)	1.65	(1.32-2.04)	9.31	(8.81-9.84)	13.53	(12.91-14.17)	7.45	(7.06-7.85)	10.12	(9.67-10.59)	17.57	(16.98-18.18)
Oregon	3.69	(3.17-4.28)	2.21	(1.82-2.67)	9.65	(9.15-10.17)	15.92	(15.26-16.59)	7.94	(7.55-8.35)	11.99	(11.51-12.48)	19.93	(19.31-20.56)
Pennsylvania	3.70	(3.40-4.01)	1.87	(1.67-2.10)	9.45	(9.19-9.73)	20.24	(19.84-20.64)	7.80	(7.59-8.02)	14.97	(14.68-15.26)	22.77	(22.42-23.13)
Rhode Island	2.22	(1.48-3.19)	2.38	(1.62-3.37)	8.47	(7.60-9.42)	17.22	(15.96-18.56)	6.68	(6.01-7.39)	12.97	(12.04-13.95)	19.64	(18.49-20.84)
South Carolina	2.99	(2.56-3.46)	1.63	(1.32-1.98)	8.77	(8.33-9.23)	17.48	(16.85-18.13)	7.11	(6.77-7.47)	12.93	(12.47-13.41)	20.05	(19.47-20.63)
South Dakota	2.85	(1.95-4.03)	1.27	(0.69-2.12)	8.14	(7.14-9.23)	14.21	(12.89-15.63)	6.62	(5.86-7.46)	10.50	(9.53-11.53)	17.12	(15.88-18.43)
Tennessee	3.47	(3.08-3.89)	2.31	(2.00-2.66)	9.01	(8.63-9.40)	21.14	(20.55-21.75)	7.42	(7.12-7.72)	15.74	(15.31-16.18)	23.16	(22.64-23.69)
Texas	3.60	(3.41-3.80)	2.43	(2.27-2.59)	8.51	(8.30-8.72)	22.44	(22.11-22.78)	7.10	(6.95-7.26)	16.70	(16.46-16.95)	23.80	(23.51-24.09)
Utah	3.90	(3.36-4.51)	1.89	(1.51-2.34)	8.77	(8.11-9.46)	22.43	(21.37-23.53)	7.37	(6.88-7.89)	16.54	(15.77-17.33)	23.91	(23.00-24.85)
Vermont	2.19	(1.29-3.50)	2.65	(1.65-4.04)	11.51	(10.20-12.94)	23.59	(21.67-25.63)	8.84	(7.86-9.90)	17.58	(16.17-19.08)	26.41	(24.69-28.23)
Virginia	3.12	(2.79-3.48)	1.36	(1.15-1.61)	8.16	(7.83-8.50)	16.19	(15.72-16.66)	6.72	(6.46-6.98)	11.93	(11.60-12.28)	18.65	(18.23-19.08)
Washington	3.69	(3.29-4.11)	2.74	(2.40-3.10)	9.52	(9.13-9.92)	24.66	(24.03-25.31)	7.85	(7.55-8.16)	18.37	(17.91-18.84)	26.22	(25.67-26.78)
West Virginia	3.34	(2.61-4.21)	1.68	(1.19-2.31)	9.28	(8.60-9.99)	16.19	(15.28-17.13)	7.57	(7.04-8.13)	12.03	(11.36-12.72)	19.60	(18.75-20.48)
Wisconsin	3.65	(3.23-4.11)	1.92	(1.62-2.25)	10.23	(9.81-10.67)	19.26	(18.67-19.87)	8.34	(8.02-8.68)	14.29	(13.86-14.73)	22.63	(22.09-23.18)
Wyoming	3.42	(2.21-5.05)	2.01	(1.12-3.31)	9.63	(8.29-11.12)	15.84	(14.13-17.69)	7.85	(6.82-8.98)	11.87	(10.62-13.23)	19.72	(18.09-21.46)

ICD-O-3 Code	Site	Total			Male			Female
ICD-O-3 Code	Site	N	Adjusted Rate	95% CI	N	Adjusted Rate	95% CI	N	Adjusted Rate	95% CI
C71.1-C71.4	Frontal, temporal, parietal, and occipital lobes of the brain	67,109	4.30	(4.27-4.33)	37,032	5.08	(5.03-5.14)	30,077	3.63	(3.59-3.67)
C71.0	Cerebrum	6,155	0.40	(0.39-0.41)	3,218	0.44	(0.43-0.46)	2,937	0.37	(0.35-0.38)
C71.5	Ventricle	3,838	0.26	(0.25-0.27)	2,101	0.28	(0.27-0.30)	1,737	0.23	(0.22-0.24)
C71.6	Cerebellum	8,799	0.59	(0.58-0.61)	4,770	0.66	(0.64-0.67)	4,029	0.53	(0.52-0.55)
C71.7	Brain stem	5,121	0.35	(0.34-0.36)	2,721	0.37	(0.36-0.39)	2,400	0.32	(0.31-0.34)
C71.8-C71.9	Other brain	31,272	2.01	(1.99-2.03)	16,264	2.28	(2.25-2.32)	15,008	1.78	(1.75-1.81)
C72.0-C72.1	Spinal cord and cauda equina	9,656	0.63	(0.62-0.64)	4,945	0.67	(0.65-0.69)	4,711	0.59	(0.58-0.61)
C72.2-C72.5	Cranial nerves	22,276	1.42	(1.40-1.44)	10,427	1.39	(1.36-1.42)	11,849	1.45	(1.42-1.47)
C72.8-C72.9	Other nervous system	2,052	0.13	(0.13-0.14)	1,099	0.15	(0.14-0.16)	953	0.12	(0.11-0.13)
C70.0-C70.9	Meninges (cerebral & spinal)	116,574	7.41	(7.37-7.46)	30,950	4.44	(4.39-4.49)	85,624	9.97	(9.90-10.04)
C75.1-C75.2	Pituitary	51,817	3.39	(3.36-3.42)	23,244	3.17	(3.13-3.21)	28,573	3.68	(3.64-3.72)
C75.3	Pineal	1,444	0.10	(0.09-0.10)	842	0.11	(0.11-0.12)	602	0.08	(0.07-0.09)
C30.0 (9522-9523)	Olfactory tumors of the nasal cavity	598	0.04	(0.04-0.04)	348	0.05	(0.04-0.05)	250	0.03	(0.03-0.04)
TOTAL		326,711	21.03	(20.96-21.11)	137,961	19.11	(19.00-19.21)	188,750	22.79	(22.68-22.89)

Histology	Total					Malignant			Non-malignant
Histology	N	% of All Tumors	Median Age	Rate	(95% CI)	N	Rate	(95% CI)	N	Rate	(95% CI)
Tumors of Neuroepithelial Tissue	101,825	31.2	56	6.60	(6.56-6.64)	94,874	6.13	(6.09-6.17)	6,951	0.47	(0.46-0.48)
Pilocytic astrocytoma	4,741	1.5	13	0.33	(0.32-0.34)	4,741	0.33	(0.32-0.34)	–	–	–
Diffuse astrocytoma	8,535	2.6	47	0.56	(0.55-0.58)	8,534	0.56	(0.55-0.58)	–	–	–
Anaplastic astrocytoma	5,621	1.7	54	0.37	(0.36-0.38)	5,621	0.37	(0.36-0.38)	–	–	–
Unique astrocytoma variants	943	0.3	22	0.06	(0.06-0.07)	626	0.04	(0.04-0.05)	317	0.02	(0.02-0.02)
Glioblastoma	50,872	15.6	64	3.19	(3.16-3.21)	50,872	3.19	(3.16-3.21)	–	–	–
Oligodendroglioma	4,020	1.2	43	0.27	(0.26-0.28)	4,020	0.27	(0.26-0.28)	–	–	–
Anaplastic oligodendroglioma	1,658	0.5	49	0.11	(0.10-0.11)	1,656	0.11	(0.10-0.11)	–	–	–
Oligoastrocytic tumors	3,045	0.9	42	0.20	(0.20-0.21)	3,043	0.20	(0.20-0.21)	–	–	–
Ependymal tumors	6,304	1.9	44	0.42	(0.41-0.43)	3,975	0.26	(0.26-0.27)	2,329	0.15	(0.15-0.16)
Glioma malignant, NOS	6,765	2.1	38	0.46	(0.44-0.47)	6,765	0.46	(0.44-0.47)	–	–	–
Choroid plexus tumors	797	0.2	19	0.05	(0.05-0.06)	123	0.01	(0.01-0.01)	674	0.05	(0.04-0.05)
Other neuroepithelial tumors	93	0.0	32	0.01	(0.01-0.01)	60	0.00	(0.00-0.01)	33	0.00	(0.00-0.00)
Neuronal and mixed neuronal-glial tumors	4,036	1.2	27	0.27	(0.26-0.28)	819	0.05	(0.05-0.06)	3,217	0.22	(0.21-0.23)
Tumors of the pineal region	605	0.2	33	0.04	(0.04-0.04)	340	0.02	(0.02-0.03)	265	0.02	(0.02-0.02)
Embryonal tumors	3,790	1.2	9	0.26	(0.26-0.27)	3,679	0.26	(0.25-0.27)	111	0.01	(0.01-0.01)
Tumors of Cranial and Spinal Nerves	26,564	8.1	55	1.69	(1.67-1.71)	241	0.02	(0.01-0.02)	26,323	1.67	(1.65-1.70)
Nerve sheath tumors	26,548	8.1	55	1.69	(1.67-1.71)	241	0.02	(0.01-0.02)	26,307	1.67	(1.65-1.69)
Other tumors of cranial and spinal nerves	16	0.0	62	0.00	(0.00-0.00)	–	–	–	16	0.00	(0.00-0.00)
Tumors of Meninges	121,110	37.1	65	7.71	(7.67-7.75)	2,525	0.16	(0.16-0.17)	118,585	7.55	(7.50-7.59)
Meningioma	116,986	35.8	65	7.44	(7.40-7.48)	1,802	0.11	(0.11-0.12)	115,184	7.33	(7.28-7.37)
Mesenchymal tumors	1,229	0.4	47	0.08	(0.08-0.09)	380	0.02	(0.02-0.03)	849	0.06	(0.05-0.06)
Primary melanocytic lesions	116	0.0	56	0.01	(0.01-0.01)	79	0.01	(0.00-0.01)	37	0.00	(0.00-0.00)
Other neoplasms related to the meninges	2,779	0.9	49	0.18	(0.17-0.19)	264	0.02	(0.02-0.02)	2,515	0.16	(0.16-0.17)
Lymphomas and Hemopoietic Neoplasms	7,122	2.2	65	0.46	(0.45-0.47)	7,084	0.46	(0.44-0.47)	38	0.00	(0.00-0.00)
Lymphoma	6,919	2.1	65	0.44	(0.43-0.46)	6,919	0.44	(0.43-0.46)	–	–	–
Other hemopoietic neoplasms	203	0.1	51	0.01	(0.01-0.02)	165	0.01	(0.01-0.01)	38	0.00	(0.00-0.00)
Germ Cell Tumors and Cysts	1,464	0.4	17	0.10	(0.10-0.11)	990	0.07	(0.06-0.07)	474	0.03	(0.03-0.04)
Germ cell tumors, cysts and heterotopias	1,464	0.4	17	0.10	(0.10-0.11)	990	0.07	(0.06-0.07)	474	0.03	(0.03-0.04
Tumors of Sellar Region	50,709	15.5	50	3.32	(3.29-3.34)	125	0.01	(0.01-0.01)	50,584	3.31	(3.28-3.34)
Tumors of the pituitary	47,958	14.7	51	3.13	(3.10-3.16)	119	0.01	(0.01-0.01)	47,839	3.12	(3.10-3.15)
Craniopharyngioma	2,751	0.8	42	0.18	(0.18-0.19)	–	–	–	2,745	0.18	(0.18-0.19)
Unclassified Tumors	17,917	5.5	64	1.16	(1.14-1.18)	6,619	0.42	(0.41-0.43)	11,298	0.73	(0.72-0.75)
Hemangioma	3,934	1.2	49	0.26	(0.25-0.27)	24	0.00	(0.00-0.00)	3,910	0.26	(0.25-0.26)
Neoplasm, unspecified	13,895	4.3	70	0.90	(0.88-0.91)	6,572	0.42	(0.41-0.43)	7,323	0.47	(0.46-0.49)
All other	88	0.0	59	0.01	(0.00-0.01)	23	0.00	(0.00-0.00)	65	0.00	(0.00-0.01)
TOTAL^‡	326,711	100.0	59	21.03	(20.96-21.11)	112,458	7.27	(7.22-7.31)	214,253	13.77	(13.71-13.83)

Histology			Age at Diagnosis								Age at Diagnosis
	0-14		0-19		20-34		35-44		45-54		55-64		65-74		75-84		85+
	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)	Rate	(95% CI)
Tumors of Neuroepithelial Tissue	3.90	(3.82-3.97)	3.59	(3.53-3.65)	3.34	(3.27-3.41)	4.48	(4.39-4.58)	6.92	(6.81-7.03)	11.70	(11.54-11.87)	17.30	(17.05-17.57)	19.55	(19.21-19.89)	12.49	(12.06-12.93)
Pilocytic astrocytoma	0.90	(0.87-0.93)	0.82	(0.79-0.85)	0.24	(0.22-0.25)	0.12	(0.11-0.14)	0.09	(0.07-0.10)	0.09	(0.07-0.10)	0.06	(0.05-0.08)	0.07	(0.05-0.09)	–	–
Diffuse astrocytoma	0.28	(0.26-0.30)	0.27	(0.26-0.29)	0.50	(0.48-0.53)	0.61	(0.58-0.65)	0.62	(0.58-0.65)	0.79	(0.75-0.83)	1.06	(1.00-1.13)	1.16	(1.08-1.25)	0.68	(0.58-0.79)
Anaplastic astrocytoma	0.08	(0.07-0.09)	0.09	(0.08-0.10)	0.27	(0.26-0.29)	0.37	(0.34-0.40)	0.44	(0.42-0.47)	0.64	(0.60-0.67)	0.92	(0.86-0.98)	0.96	(0.89-1.04)	0.39	(0.32-0.48)
Unique astrocytoma variants	0.10	(0.09-0.11)	0.10	(0.09-0.11)	0.06	(0.05-0.07)	0.04	(0.03-0.05)	0.04	(0.03-0.05)	0.04	(0.03-0.05)	0.05	(0.04-0.07)	0.06	(0.04-0.08)	0.07	(0.04-0.11)
Glioblastoma	0.14	(0.12-0.15)	0.14	(0.13-0.16)	0.40	(0.37-0.42)	1.20	(1.16-1.25)	3.62	(3.54-3.70)	8.08	(7.94-8.21)	13.09	(12.86-13.31)	14.93	(14.63-15.23)	9.24	(8.87-9.62)
Oligodendroglioma	0.04	(0.03-0.05)	0.06	(0.05-0.06)	0.31	(0.29-0.33)	0.48	(0.45-0.51)	0.42	(0.39-0.44)	0.33	(0.30-0.36)	0.26	(0.23-0.29)	0.21	(0.17-0.25)	0.10	(0.06-0.14)
Anaplastic oligodendroglioma	0.01	(0.00-0.01)	0.01	(0.01-0.01)	0.09	(0.08-0.10)	0.18	(0.16-0.19)	0.18	(0.16-0.20)	0.20	(0.18-0.22)	0.18	(0.15-0.20)	0.12	(0.09-0.15)	–	–
Oligoastrocytic tumors	0.03	(0.03-0.04)	0.04	(0.03-0.04)	0.28	(0.26-0.30)	0.34	(0.31-0.36)	0.28	(0.26-0.30)	0.26	(0.24-0.29)	0.22	(0.19-0.25)	0.16	(0.13-0.20)	–	–
Ependymal tumors	0.28	(0.26-0.30)	0.28	(0.26-0.29)	0.37	(0.35-0.39)	0.48	(0.45-0.51)	0.59	(0.56-0.62)	0.57	(0.53-0.61)	0.54	(0.49-0.58)	0.39	(0.35-0.45)	0.15	(0.11-0.21)
Glioma malignant, NOS	0.73	(0.70-0.76)	0.61	(0.59-0.64)	0.24	(0.22-0.26)	0.25	(0.23-0.27)	0.27	(0.25-0.30)	0.38	(0.35-0.41)	0.62	(0.57-0.67)	1.21	(1.12-1.29)	1.60	(1.44-1.76)
Choroid plexus tumors	0.12	(0.10-0.13)	0.10	(0.09-0.11)	0.04	(0.03-0.04)	0.04	(0.03-0.05)	0.04	(0.03-0.05)	0.03	(0.02-0.04)	0.03	(0.02-0.04)	0.05	(0.04-0.07)	–	–
Other neuroepithelial tumors	0.01	(0.01-0.01)	0.01	(0.01-0.01)	0.01	(0.00-0.01)	–	–	–	–	–	–	–	–	–	–	–	–
Neuronal and mixed neuronal-glial tumors	0.33	(0.31-0.35)	0.36	(0.34-0.38)	0.31	(0.29-0.33)	0.24	(0.21-0.26)	0.21	(0.19-0.23)	0.21	(0.19-0.23)	0.20	(0.18-0.23)	0.16	(0.13-0.19)	0.07	(0.04-0.12)
Tumors of the pineal region	0.04	(0.04-0.05)	0.04	(0.04-0.05)	0.05	(0.04-0.05)	0.04	(0.03-0.05)	0.05	(0.04-0.06)	0.04	(0.03-0.05)	0.03	(0.02-0.05)	–	–	–	–
Embryonal tumors	0.80	(0.77-0.84)	0.66	(0.64-0.69)	0.18	(0.16-0.19)	0.10	(0.09-0.12)	0.08	(0.07-0.09)	0.05	(0.04-0.06)	0.05	(0.04-0.07)	0.05	(0.03-0.07)	–	–
Tumors of Cranial and Spinal Nerves	0.25	(0.23-0.26)	0.27	(0.25-0.28)	0.78	(0.74-0.81)	1.73	(1.67-1.79)	2.82	(2.75-2.89)	3.86	(3.76-3.95)	4.24	(4.11-4.37)	3.36	(3.22-3.50)	1.85	(1.69-2.03)
Nerve sheath tumors	0.25	(0.23-0.26)	0.27	(0.25-0.28)	0.77	(0.74-0.81)	1.73	(1.67-1.79)	2.82	(2.75-2.89)	3.85	(3.76-3.95)	4.23	(4.11-4.36)	3.36	(3.22-3.50)	1.85	(1.68-2.02)
Other tumors of cranial and spinal nerves	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Tumors of Meninges	0.14	(0.13-0.16)	0.20	(0.19-0.22)	1.57	(1.53-1.62)	4.79	(4.70-4.88)	8.95	(8.82-9.07)	14.60	(14.41-14.78)	24.96	(24.65-25.27)	37.12	(36.65-37.59)	49.17	(48.32-50.04)
Meningioma	0.09	(0.08-0.10)	0.13	(0.12-0.14)	1.32	(1.28-1.37)	4.46	(4.37-4.55)	8.58	(8.46-8.70)	14.13	(13.95-14.31)	24.48	(24.17-24.79)	36.70	(36.23-37.17)	48.95	(48.10-49.82)
Mesenchymal tumors	0.04	(0.03-0.05)	0.04	(0.03-0.04)	0.06	(0.05-0.07)	0.10	(0.09-0.12)	0.09	(0.08-0.11)	0.14	(0.12-0.16)	0.14	(0.12-0.16)	0.11	(0.09-0.14)	0.08	(0.05-0.12)
Primary melanocytic lesions	–	–	0.00	(0.00-0.01)	–	–	–	–	0.01	(0.01-0.01)	0.01	(0.01-0.02)	0.02	(0.02-0.04)	–	–	–	–
Other neoplasms related to the meninges	0.01	(0.01-0.02)	0.03	(0.03-0.04)	0.18	(0.17-0.20)	0.23	(0.21-0.25)	0.26	(0.24-0.28)	0.31	(0.29-0.34)	0.32	(0.28-0.35)	0.28	(0.24-0.33)	0.13	(0.09-0.18)
Lymphomas and Hemopoietic Neoplasms	0.02	(0.02-0.03)	0.02	(0.02-0.03)	0.12	(0.11-0.13)	0.28	(0.25-0.30)	0.46	(0.43-0.49)	0.88	(0.83-0.92)	1.90	(1.81-1.98)	2.25	(2.14-2.37)	1.10	(0.98-1.24)
Lymphoma	0.01	(0.01-0.02)	0.01	(0.01-0.02)	0.11	(0.10-0.12)	0.27	(0.24-0.29)	0.45	(0.42-0.48)	0.85	(0.81-0.90)	1.86	(1.78-1.95)	2.24	(2.12-2.36)	1.08	(0.96-1.22)
Other hemopoietic neoplasms	0.01	(0.01-0.01)	0.01	(0.01-0.01)	0.01	(0.00-0.01)	0.01	(0.01-0.02)	0.01	(0.01-0.02)	0.03	(0.02-0.04)	0.03	(0.02-0.04)	–	–	–	–
Germ Cell Tumors and Cysts	0.19	(0.17-0.21)	0.21	(0.20-0.23)	0.11	(0.10-0.12)	0.05	(0.04-0.06)	0.03	(0.02-0.04)	0.02	(0.01-0.03)	0.03	(0.02-0.04)	0.03	(0.02-0.05)	–	–
Germ cell tumors, cysts and heterotopias	0.19	(0.17-0.21)	0.21	(0.20-0.23)	0.11	(0.10-0.12)	0.05	(0.04-0.06)	0.03	(0.02-0.04)	0.02	(0.01-0.03)	0.03	(0.02-0.04)	0.03	(0.02-0.05)	–	–
Tumors of Sellar Region	0.40	(0.38-0.43)	0.69	(0.66-0.71)	2.93	(2.87-2.99)	3.91	(3.83-4.00)	4.38	(4.29-4.47)	5.23	(5.12-5.34)	7.03	(6.86-7.19)	6.82	(6.62-7.03)	4.70	(4.44-4.97)
Tumors of the pituitary	0.19	(0.18-0.21)	0.49	(0.47-0.52)	2.81	(2.75-2.87)	3.75	(3.67-3.84)	4.17	(4.09-4.26)	4.99	(4.89-5.10)	6.76	(6.60-6.93)	6.61	(6.41-6.82)	4.60	(4.34-4.87)
Craniopharyngioma	0.21	(0.19-0.23)	0.20	(0.18-0.21)	0.12	(0.11-0.13)	0.16	(0.14-0.18)	0.21	(0.19-0.23)	0.24	(0.21-0.26)	0.26	(0.23-0.30)	0.21	(0.17-0.25)	0.10	(0.07-0.15)
Unclassified Tumors	0.24	(0.22-0.26)	0.28	(0.26-0.29)	0.54	(0.51-0.57)	0.76	(0.73-0.80)	1.03	(0.99-1.08)	1.46	(1.40-1.52)	2.52	(2.42-2.62)	5.18	(5.01-5.36)	11.64	(11.22-12.06)
Hemangioma	0.07	(0.06-0.08)	0.09	(0.08-0.10)	0.22	(0.20-0.24)	0.31	(0.28-0.33)	0.37	(0.34-0.39)	0.41	(0.38-0.45)	0.42	(0.38-0.46)	0.44	(0.39-0.49)	0.33	(0.26-0.40)
Neoplasm, unspecified	0.17	(0.15-0.18)	0.19	(0.18-0.20)	0.32	(0.30-0.34)	0.45	(0.42-0.48)	0.66	(0.63-0.70)	1.04	(0.99-1.09)	2.08	(1.99-2.17)	4.73	(4.56-4.90)	11.27	(10.87-11.69)
All other	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
TOTAL^‡	5.14	(5.05-5.22)	5.26	(5.19-5.33)	9.38	(9.27-9.49)	16.01	(15.84-16.18)	24.59	(24.38-24.80)	37.74	(37.45-38.04)	57.97	(57.50-58.44)	74.31	(73.64-74.98)	80.99	(79.89-82.10)

Age (years)	Most Common Histology			Second Most Common Histology			Third Most Common Histology			Fourth Most Common Histology
Age (years)	Histology	Rate^‡	(95% CI)	Histology	Rate	(95% CI)	Histology	Rate	(95% CI)	Histology	Rate	(95% CI)
0-4	Embryonal Tumors	1.27	(1.20-1.35)	Pilocytic Astrocytoma	0.96	(0.90-1.03)	Glioma Malignant, NOS	0.90	(0.84-0.96)	Ependymal Tumors	0.43	(0.39-0.48)
5-9	Pilocytic Astrocytoma	0.91	(0.85-0.97)	Glioma Malignant, NOS	0.86	(0.80-0.92)	Embryonal Tumors	0.75	(0.70-0.80)	Neuronal and Mixed Neuronal Glial Tumors	0.31	(0.28-0.35)
10-14	Pilocytic Astrocytoma	0.83	(0.77-0.89)	Glioma Malignant, NOS	0.45	(0.41-0.49)	Neuronal and Mixed Neuronal Glial Tumors	0.42	(0.39-0.47)	Embryonal Tumors	0.41	(0.38-0.46)
15-19	Tumors of the Pituitary	1.39	(1.32-1.46)	Pilocytic Astrocytoma	0.58	(0.54-0.63)	Neuronal and Mixed Neuronal Glial Tumors	0.44	(0.41-0.49)	Nerve Sheath Tumors	0.33	(0.30-0.37)
20-34	Tumors of the Pituitary	2.81	(2.75-2.87)	Meningioma	1.32	(1.28-1.37)	Nerve Sheath Tumors	0.77	(0.74-0.81)	Diffuse Astrocytoma	0.50	(0.48-0.53)
35-44	Meningioma	4.46	(4.37-4.55)	Tumors of the Pituitary	3.75	(3.67-3.84)	Nerve Sheath Tumors	1.73	(1.67-1.79)	Glioblastoma	1.20	(1.16-1.25)
45-54	Meningioma	8.58	(8.46-8.70)	Tumors of the Pituitary	4.17	(4.09-4.26)	Glioblastoma	3.62	(3.54-3.70)	Nerve Sheath Tumors	2.82	(2.75-2.89)
55-64	Meningioma	14.13	(13.95-14.31)	Glioblastoma	8.08	(7.94-8.21)	Tumors of the Pituitary	4.99	(4.89-5.10)	Nerve Sheath Tumors	3.85	(3.76-3.95)
65-74	Meningioma	24.48	(24.17-24.79)	Glioblastoma	13.1	(12.86-13.31)	Tumors of the Pituitary	6.76	(6.6-6.93)	Nerve Sheath Tumors	4.23	(4.11-4.36)
75-84	Meningioma	36.70	(36.23-37.17)	Glioblastoma	14.9	(14.63-15.23)	Tumors of the Pituitary	6.61	(6.41-6.82)	Nerve Sheath Tumors	3.36	(3.22-3.50)
85+	Meningioma	48.95	(48.1-49.82)	Glioblastoma	9.24	(8.87-9.62)	Tumors of the Pituitary	4.60	(4.34-4.87)	Nerve Sheath Tumors	1.85	(1.68-2.02)
Overall	Meningioma	7.44	(7.40-7.48)	Glioblastoma	3.19	(3.16-3.21)	Tumors of the Pituitary	3.13	(3.10-3.16)	Nerve Sheath Tumors	1.69	(1.67-1.71)

ICCC Category	0-19 years			0-14 years		< 1 year		1-4 years		5-9 years		10-14 years		15-19 years
ICCC Category	Count	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI	Rate	95% CI
II Lymphomas and reticuloendothelial neoplasms	80	0.02	(0.02-0.02)	0.02	(0.01-0.02)	–	–	–	–	0.02	(0.01-0.03)	0.02	(0.01-0.03)	0.03	(0.02-0.04)
III CNS and misc. intracranial and intraspinal neoplasms	18,326	4.49	(4.42-4.55)	4.46	(4.39-4.54)	4.91	(4.61-5.23)	5.11	(4.95-5.27)	4.32	(4.20-4.46)	4.02	(3.90-4.15)	4.56	(4.44-4.69)
III(a) Ependymomas and choroid plexus tumor	1,539	0.37	(0.36-0.39)	0.40	(0.38-0.42)	0.95	(0.82-1.10)	0.65	(0.59-0.71)	0.26	(0.23-0.30)	0.24	(0.22-0.28)	0.3	(0.27-0.33)
III(b) Astrocytomas	6,465	1.59	(1.55-1.63)	1.71	(1.66-1.75)	1.45	(1.29-1.63)	2.04	(1.94-2.14)	1.68	(1.60-1.76)	1.53	(1.45-1.61)	1.25	(1.18-1.32)
III(c) Intracranial and intraspinal embryonal tumors	2,478	0.61	(0.59-0.64)	0.74	(0.71-0.77)	1.25	(1.10-1.41)	1.10	(1.03-1.18)	0.71	(0.66-0.77)	0.4	(0.36-0.44)	0.23	(0.20-0.26)
III(d) Other gliomas	2,264	0.56	(0.54-0.58)	0.61	(0.58-0.64)	0.31	(0.23-0.39)	0.64	(0.59-0.7)	0.75	(0.70-0.81)	0.5	(0.46-0.55)	0.41	(0.37-0.45)
III(e) Other specified intracranial and intraspinal neoplasms	4,805	1.16	(1.13-1.19)	0.83	(0.80-0.87)	0.62	(0.52-0.74)	0.53	(0.48-0.58)	0.78	(0.72-0.83)	1.17	(1.10-1.23)	2.13	(2.04-2.22)
III(f) Unspecified intracranial and intraspinal neoplasms	775	0.19	(0.18-0.20)	0.17	(0.15-0.18)	0.33	(0.26-0.42)	0.15	(0.12-0.18)	0.14	(0.12-0.17)	0.18	(0.16-0.21)	0.25	(0.22-0.28)
IV Neuroblastoma and other peripheral nervous cell tumors	171	0.04	(0.04-0.05)	0.05	(0.04-0.06)	0.26	(0.19-0.34)	0.08	(0.06-0.11)	0.02	(0.01-0.03)	–	–	0.02	(0.01-0.03)
IX Soft tissue and other extraosseous sarcomas	77	0.02	(0.01-0.02)	0.02	(0.01-0.02)	–	–	0.02	(0.01-0.03)	0.02	(0.01-0.03)	0.02	(0.01-0.03)	0.02	(0.01-0.03)
X(a) Intracranial & intraspinal germ cell tumors	148	0.04	(0.03-0.04)	0.05	(0.04-0.05)	0.26	(0.19-0.34)	0.08	(0.06-0.1)	0.02	(0.01-0.03)	0.01	(0.00-0.01)	0.01	(0.00-0.01)
All other categories	30	0.01	(0.00-0.01)	0.01	(0.00-0.01)	–	–	–	–	–	–	–	–	–	–
Not classified by ICCC	1,962	0.48	(0.45-0.50)	0.39	(0.37-0.41)	6.14	(5.80-6.50)	5.68	(5.52-5.85)	4.89	(4.75-5.03)	4.78	(4.64-4.91)	5.64	(5.50-5.78)
TOTAL^§	21,512	5.26	(5.19-5.33)	5.14	(5.05-5.22)	6.14	(5.80-6.50)	5.68	(5.52-5.85)	4.89	(4.75-5.03)	4.78	(4.64-4.91)	5.64	(5.50-5.78)

Histology	ICD-O-3^‡ Histology Code
Tumors of Neuroepithelial Tissue
Pilocytic astrocytoma	9421/1 [Included with malignant tumors as explained in Brain Tumor Definition Differences]
Unique astrocytoma variants	9384/1
Ependymal tumors	9383/1; 9394/1
Choroid plexus	9390/0,1
Other neuroepithelial tumors	9363/0; 9444/1
Neuronal and mixed neuronal-	8680/0,1; 8681/1; 8690/1; 8693/1; 9412/1; 9413/0; 9442/1;
glial tumors	9492/0 (excluding site C75.1); 9493/0; 9505/1; 9506/1
Tumors of the pineal region	9360/1; 9361/1
Embryonal tumors	9490/0
Tumors of Cranial and Spinal Nerves
Nerve sheath tumors	9540/0,1; 9541/0, 9550/0; 9560/0,1; 9570/0; 9571/0
Other tumors of cranial and spinal nerves	9562/0
Tumors of Meninges
Meningioma	9530/0,1; 9531/0; 9532/0; 9533/0; 9534/0; 9537/0; 9538/1; 9539/1
Mesenchymal tumors	8324/0; 8800/0; 8810/0; 8815/0; 8824/0,1; 8830/0,1; 8831/0; 8835/1; 8836/1;
	8850/0,1; 8851/0; 8852/0, 8854/0; 8857/0; 8861/0; 8870/0; 8880/0, 8890/0,1; 8897/1;
	8900/0; 8920/1; 8935/0,1; 8990/0,1; 9040/0; 9136/1, 9150/0,1; 9170/0; 9180/0; 9210/0; 9241/0; 9373/0
Primary melanocytic lesions	8728/0,1; 8770/0; 8771/0
Other neoplasms related to the meninges	9161/1; 9220/0,1; 9535/0
Lymphomas and Hemopoietic Neoplasms
Other hemopoietic neoplasms	9740/1; 9751/1; 9752/1; 9753/1; 9766/1; 9970/1
Germ Cell Tumors and Cysts
Germ cell tumors, cysts and heterotopias	8440/0; 9080/0,1; 9084/0
Tumors of Sellar Region
Tumors of the pituitary	8040/0,1; 8140/0,1; 8146/0; 8260/0; 8270/0; 8271/0; 8272/0;
	8280/0; 8281/0; 8290/0; 8300/0; 8310/0; 8323/0; 9492/0 (site C75.1 only); 9582/0
Craniopharyngioma	9350/1; 9351/1; 9352/1
Unclassified Tumors
Hemangioma	9120/0; 9121/0; 9122/0; 9123/0; 9125/0; 9130/0,1; 9131/0; 9133/1
Neoplasm, unspecified	8000/0,1; 8001/0,1; 8005/0; 8010/0
All other	8452/1; 8711/0; 8713/0; 8811/0; 8840/0; 9173/0; 9580/0

STATE	2013 Estimated New Cases			2014 Estimated New Cases
STATE	All	Malignant	Non-Malignant	All	Malignant	Non-Malignant
Alabama	770	340	440	780	340	440
Alaska	160	60	110	170	60	110
Arizona	1,470	520	960	1,510	530	980
Arkansas	580	210	370	580	210	370
California	7,700	2,660	5,040	7,790	2,690	5,090
Colorado	1,310	360	950	1,320	370	960
Connecticut	690	280	410	690	280	410
Delaware	180	70	110	180	70	110
District of Columbia	100	–	60	100	–	60
Florida	4,560	1,460	3,100	4,650	1,490	3,160
Georgia	2,090	690	1,400	2,110	700	1,420
Hawaii	250	70	180	250	70	180
Idaho	310	120	190	310	120	190
Illinois	2,840	940	1,890	2,850	950	1,900
Indiana	1,330	490	840	1,340	490	840
Iowa	640	240	400	640	240	400
Kansas	530	200	330	540	200	330
Kentucky	1100	340	760	1,110	340	760
Louisiana	920	300	620	920	300	620
Maine	240	110	130	240	110	130
Maryland	1,160	420	740	1,170	420	740
Massachusetts	1,260	530	730	1,260	530	730
Michigan	2,250	800	1,450	2,250	800	1,450
Mississippi	580	200	380	580	200	380
Missouri	1,310	440	870	1,320	450	870
Montana	210	70	140	210	70	140
Nebraska	340	140	200	340	140	200
Nevada	460	180	280	480	190	290
New Hampshire	280	120	160	280	120	160
New Jersey	1,820	710	1,110	1,830	710	1,120
New Mexico	340	120	220	340	120	220
New York	4,590	1,440	3,150	4,590	1,440	3,150
North Carolina	2,050	700	1,350	2,070	710	1,370
North Dakota	100	–	60	100	–	60
Ohio	2,040	870	1,180	2,040	870	1,180
Oklahoma	640	270	370	640	270	370
Oregon	780	310	470	790	310	480
Pennsylvania	2,880	990	1,900	2,890	990	1,900
Rhode Island	220	80	150	220	80	150

Histology	N	1-Yr		2-Yr		3-Yr		4-Yr		5-Yr		10-Yr
Histology	N	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Pilocytic astrocytoma	3,301	97.9	(97.4-98.4)	96.8	(96.1-97.4)	95.7	(94.9-96.4)	95.0	(94.0-95.8)	94.4	(93.4-95.2)	91.9	(90.5-93.1)
Diffuse astrocytoma	5,902	71.3	(70.1-72.5)	60.6	(59.3-61.9)	54.5	(53.1-55.8)	50.3	(48.9-51.7)	47.3	(45.8-48.7)	36.4	(34.7-38.1)
Anaplastic astrocytoma	3,472	60.1	(58.4-61.8)	42.1	(40.3-43.8)	34.1	(32.3-35.8)	29.7	(28-31.4)	26.5	(24.8-28.2)	18.1	(16.4-20.0)
Glioblastoma	28,212	35.0	(34.4-35.6)	13.7	(13.3-14.1)	8.0	(7.6-8.3)	5.8	(5.5-6.2)	4.7	(4.4-5.0)	2.4	(2.1-2.7)
Oligodendroglioma	3,226	93.8	(92.9-94.6)	89.5	(88.3-90.6)	85.7	(84.3-86.9)	82.2	(80.7-83.7)	79.1	(77.4-80.7)	62.6	(60.1-64.9)
Anaplastic oligodendroglioma	1,257	80.6	(78.2-82.8)	67.7	(64.8-70.3)	60.8	(57.8-63.6)	55.4	(52.3-58.3)	50.7	(47.5-53.8)	37.3	(33.5-41.2)
Ependymal tumors	2,517	93.9	(92.8-94.8)	89.7	(88.3-90.9)	86.7	(85.1-88.1)	84.8	(83.1-86.4)	83.4	(81.5-85.1)	78.8	(76.3-81.1)
Oligoastrocytic tumors	1,820	87.2	(85.5-88.7)	76.9	(74.7-78.9)	70.6	(68.3-72.9)	65.2	(62.7-67.7)	61.0	(58.3-63.6)	47.8	(44.3-51.2)
Glioma malignant, NOS	4,014	61.1	(59.5-62.6)	50.3	(48.7-52.0)	46.8	(45.2-48.5)	44.9	(43.2-46.5)	43.4	(41.7-45.1)	38.3	(36.3-40.3)
Neuronal and mixed neuronal-glial tumors	469	90.2	(86.9-92.7)	82.8	(78.7-86.3)	78.8	(74.3-82.7)	75.2	(70.2-79.4)	74.5	(69.4-78.9)	59.5	(51.5-66.6)
Embryonal tumors	2,666	81.5	(80.0-83.0)	71.9	(70.1-73.6)	66.7	(64.8-68.6)	63.7	(61.7-65.6)	61.3	(59.2-63.3)	54.2	(51.8-56.5)
Medulloblastoma	1,573	88.2	(86.5-89.7)	81.7	(79.6-83.6)	76.8	(74.5-78.9)	73.8	(71.3-76.1)	71.1	(68.5-73.5)	62.8	(59.7-65.8)
Primative neuroectodermal tumor	651	76.4	(72.9-79.6)	61.3	(57.2-65)	55.2	(51.1-59.1)	51.8	(47.6-55.8)	49.5	(45.3-53.6)	42.8	(38.4-47.2)
Atypical teratoid/rhabdoid tumor	181	48.1	(40.3-55.5)	34.6	(27.1-42.1)	29.2	(21.9-36.9)	28.0	(20.7-35.7)	28.0	(20.7-35.7)	26.2	(18.8-34.3)
Other embryonal histologies	261	76.3	(70.5-81.1)	64.4	(58.0-70.2)	59.7	(52.9-65.7)	56.8	(50.0-63.1)	54.2	(47.2-60.7)	51.6	(44.3-58.5)
Meningioma	1,099	82.6	(80.0-84.8)	75.0	(72.0-77.8)	70.2	(67.0-73.3)	68.0	(64.6-71.2)	64.7	(61.0-68.1)	56.3	(51.6-60.8)
Lymphoma	4,500	47.6	(46.1-49.1)	38.9	(37.4-40.4)	34.4	(32.9-35.9)	31.3	(29.8-32.8)	29.1	(27.5-30.6)	21.8	(20.0-23.6)
Total: All Brain and Other Nervous System^∥	66,830	56.9	(56.5-57.3)	43.1	(42.7-43.5)	38.2	(37.8-38.6)	35.6	(35.2-36)	33.8	(33.4-34.2)	28.1	(27.7-28.6)

State	TOTAL			Males			Females
State	N	Rate	95% CI	N	Rate	95% CI	N	Rate	95% CI
Alabama	1,229	4.78	(4.51, 5.06)	666	5.69	(5.26, 6.15)	563	3.99	(3.66, 4.34)
Alaska	114	4.29	(3.47, 5.24)	65	5.09	(3.74, 6.73)	49	3.70	(2.68, 4.96)
Arizona	1,332	4.05	(3.83, 4.28)	745	4.83	(4.48, 5.19)	587	3.36	(3.09, 3.65)
Arkansas	786	4.93	(4.58, 5.29)	431	5.96	(5.4, 6.56)	355	4.07	(3.65, 4.53)
California	7,509	4.24	(4.15, 4.34)	4,210	5.17	(5.01, 5.33)	3,299	3.46	(3.34, 3.58)
Colorado	1,056	4.48	(4.20, 4.76)	606	5.49	(5.04, 5.96)	450	3.61	(3.28, 3.97)
Connecticut	842	4.24	(3.95, 4.54)	464	5.20	(4.73, 5.70)	378	3.44	(3.09, 3.81)
Delaware	203	4.20	(3.64, 4.83)	118	5.46	(4.50, 6.57)	85	3.20	(2.55, 3.98)
Washington DC	103	3.62	(2.94, 4.41)	56	4.49	(3.36, 5.87)	47	2.93	(2.13, 3.92)
Florida	4,470	3.91	(3.79, 4.03)	2,526	4.82	(4.63, 5.01)	1,944	3.13	(2.99, 3.27)
Georgia	1,730	3.96	(3.77, 4.15)	944	4.79	(4.47, 5.12)	786	3.31	(3.08, 3.55)
Hawaii	173	2.29	(1.96, 2.67)	100	2.86	(2.32, 3.49)	73	1.83	(1.42, 2.31)
Idaho	375	4.92	(4.42, 5.45)	214	5.81	(5.04, 6.65)	161	4.06	(3.45, 4.74)
Illinois	2,623	3.99	(3.84, 4.15)	1,451	4.88	(4.63, 5.14)	1,172	3.27	(3.08, 3.46)
Indiana	1,526	4.51	(4.28, 4.74)	832	5.40	(5.03, 5.79)	694	3.77	(3.49, 4.07)
Iowa	911	5.37	(5.02, 5.73)	523	6.71	(6.14, 7.32)	388	4.24	(3.82, 4.70)
Kansas	713	4.84	(4.48, 5.21)	409	5.99	(5.42, 6.61)	304	3.79	(3.37, 4.25)
Kentucky	1,072	4.61	(4.34, 4.90)	583	5.46	(5.01, 5.93)	489	3.88	(3.54, 4.24)
Louisiana	983	4.33	(4.06, 4.62)	538	5.18	(4.74, 5.65)	445	3.58	(3.25, 3.93)
Maine	408	5.03	(4.54, 5.55)	231	6.20	(5.41, 7.08)	177	4.06	(3.47, 4.73)
Maryland	1,144	3.86	(3.64, 4.09)	629	4.73	(4.36, 5.13)	515	3.17	(2.89, 3.46)
Massachusetts	1,520	4.22	(4.01, 4.44)	848	5.30	(4.95, 5.68)	672	3.34	(3.09, 3.61)
Michigan	2,629	4.86	(4.68, 5.06)	1,489	6.02	(5.71, 6.34)	1,140	3.91	(3.68, 4.15)
Minnesota	1,231	4.45	(4.20, 4.71)	686	5.34	(4.94, 5.76)	545	3.69	(3.38, 4.02)
Mississippi	672	4.42	(4.09, 4.77)	344	5.14	(4.60, 5.73)	328	3.88	(3.47, 4.33)
Missouri	1,473	4.52	(4.29, 4.76)	806	5.41	(5.03, 5.80)	667	3.77	(3.49, 4.08)
Montana	250	4.44	(3.89, 5.04)	147	5.37	(4.52, 6.34)	103	3.60	(2.92, 4.39)
Nebraska	473	4.95	(4.51, 5.42)	255	5.79	(5.09, 6.55)	218	4.13	(3.59, 4.74)
Nevada	528	4.03	(3.69, 4.40)	341	5.47	(4.88, 6.12)	187	2.76	(2.38, 3.20)
New Hampshire	351	4.86	(4.36, 5.41)	212	6.31	(5.47, 7.24)	139	3.63	(3.04, 4.31)
New Jersey	1,735	3.66	(3.49, 3.84)	980	4.62	(4.33, 4.93)	755	2.88	(2.67, 3.09)
New Mexico	391	3.68	(3.32, 4.07)	221	4.36	(3.80, 4.99)	170	3.06	(2.61, 3.57)
New York	3,884	3.73	(3.61, 3.85)	2,185	4.73	(4.53, 4.93)	1,699	2.93	(2.79, 3.08)
North Carolina	1,978	4.09	(3.91, 4.27)	1,096	5.06	(4.76, 5.38)	882	3.30	(3.08, 3.52)
North Dakota	162	4.47	(3.80, 5.23)	86	5.12	(4.08, 6.35)	76	3.79	(2.97, 4.78)
Ohio	2,864	4.48	(4.32, 4.65)	1,575	5.41	(5.14, 5.69)	1,289	3.68	(3.48, 3.89)
Oklahoma	908	4.61	(4.31, 4.92)	498	5.47	(4.99, 5.98)	410	3.83	(3.46, 4.22)
Oregon	1,020	4.91	(4.60, 5.22)	595	6.07	(5.59, 6.59)	425	3.90	(3.53, 4.29)
Pennsylvania	3,086	4.12	(3.97, 4.27)	1,671	4.95	(4.71, 5.20)	1,415	3.43	(3.25, 3.62)

ICD-O-3 CODE	SITE^‡	N	1-Yr		2-Yr		5-Yr		10-Yr
ICD-O-3 CODE	SITE^‡	N	%	95% CI	%	95% CI	%	95% CI	%	95% CI
C71.1	Frontal lobe of the brain	14,973	59.6	(58.8-60.5)	45.3	(44.4-46.1)	34.4	(33.6-35.3)	25.9	(24.9-26.9)
C71.2	Temporal lobe of the brain	10,748	54.1	(53.1-55.1)	33.8	(32.8-34.7)	22.3	(21.4-23.2)	16.9	(16.0-17.9)
C71.3	Parietal lobe of the brain	7,265	47.0	(45.8-48.2)	28.9	(27.8-30.1)	18.9	(17.9-20.0)	13.4	(12.3-14.5)
C71.4	Occipital lobe of the brain	1,807	49.1	(46.7-51.5)	30.5	(28.2-32.7)	20.8	(18.7-23.0)	17.2	(15.0-19.6)
C71.0	Cerebrum	3,288	48.2	(46.4-49.9)	34.3	(32.6-36.0)	25.8	(24.2-27.5)	22.4	(20.7-24.2)
C71.5	Ventricle	1,205	74.4	(71.5-76.6)	66.9	(64.3-69.8)	61.3	(58.2-64.3)	57.1	(53.5-60.4)
C71.6	Cerebellum	3,689	84.5	(83.2-85.7)	78.3	(76.8-79.6)	70.8	(69.2-72.4)	66.0	(64.0-67.9)
C71.7	Brain stem	3,004	68.7	(66.9-70.4)	56.2	(54.3-58.0)	47.7	(45.7-49.7)	42.6	(40.4-44.8)
C71.8-C71.9	Other brain	14,718	41.5	(40.6-42.3)	29.7	(28.9-30.5)	21.3	(20.6-22.1)	16.9	(16.1-17.7)
C72.0-C72.1	Spinal cord and cauda equina	2,257	88.8	(87.3-90.1)	84.4	(82.7-86.0)	79.7	(77.6-81.7)	75.4	(72.6-78.0)
C72.2-C72.5	Cranial nerves	676	96.2	(94.3-97.4)	94.3	(92.1-95.9)	91.9	(89.1-94.0)	90.4	(87.0-93.0)
C72.8-C72.9	Other nervous system	631	59.4	(55.3-63.2)	50.6	(46.4-54.7)	43.5	(38.9-47.9)	38.8	(33.7-43.9)
C70.0-C70.9	Meninges (cerebral and spinal)	1,257	81.6	(79.7-84.2)	74.4	(71.6-77.0)	63.8	(60.4-67.0)	56.0	(51.6-60.1)
C75.1-C75.2	Pituitary and craniopharyngeal duct	265	84.2	(79.0-88.2)	80.1	(74.3-84.8)	71.2	(64.2-77.0)	62.7	(54.2-70.1)
C75.3	Pineal	681	87.5	(84.7-89.8)	81.1	(77.8-84.0)	73.8	(69.9-77.4)	68.3	(63.2-72.9)
C30.0 (9522-9523)	Olfactory tumors of the nasal cavity	366	89.7	(85.8-92.6)	83.1	(78.4-86.9)	75.7	(69.9-80.5)	61.4	(52.5-69.1)
All Codes	All Sites	66,830	56.9	(56.5-57.3)	43.1	(42.7-43.5)	33.8	(33.4-34.2)	28.1	(27.7-28.6)

Histology	Age Group	N	1-Yr		2-Yr		5-Yr		10-Yr
Histology	Age Group	N	%	95% CI	%	95% CI	%	95% CI	%	95% CI
Pilocytic astrocytoma	0-14 yr	1,988	98.7	(98.1-99.1)	98.5	(97.8-99.0)	97.2	(96.3-98.0)	96.2	(94.9-97.2)
	0-19 yr	2,386	98.5	(98.0-99.0)	98.3	(97.7-98.8)	96.8	(95.9-97.6)	96.0	(94.8-96.9)
	20-44 yr	680	96.7	(95.0-97.9)	94.8	(92.7-96.3)	90.4	(87.5-92.6)	84.6	(80.5-88.0)
	45-54 yr	124	94.4	(88.1-97.4)	86.4	(78.2-91.7)	78.7	(68.8-85.7)	73.8	(61.8-82.5)
	55-64 yr	69	97.5	(86.8-99.5)	90.2	(76.6-96.1)	84.1	(68.7-92.3)	66.4	(45.2-81.0)
	65-74 yr	26	85.6	(63.1-94.9)	–	–	–	–	–	–
	75+ yr	–	–	–	–	–	–	–	–	–
Diffuse astrocytoma	0-14 yr	706	91.2	(88.8-93.1)	87.0	(84.1-89.4)	82.7	(79.4-85.5)	80.7	(77.0-83.9)
	0-19 yr	890	92.4	(90.3-94.0)	87.3	(84.8-89.5)	82.7	(79.8-85.3)	80.4	(77.1-83.3)
	20-44 yr	2,088	92.2	(90.9-93.3)	84.9	(83.2-86.4)	64.8	(62.4-67.1)	45.3	(42.3-48.4)
	45-54 yr	932	73.3	(70.2-76.1)	58.5	(55.1-61.8)	42.5	(38.9-46.1)	30.0	(25.7-34.4)
	55-64 yr	812	53.4	(49.8-56.9)	33.4	(29.9-36.9)	21.0	(17.7-24.4)	12.5	(9.0-16.6)
	65-74 yr	630	35.8	(31.9-39.7)	22.1	(18.7-25.6)	12.9	(10.0-16.3)	7.3	(3.9-11.9)
	75+ yr	550	19.8	(16.4-23.5)	9.5	(7.0-12.5)	4.7	(2.7-7.6)	0.8	(0.1-3.9)
Anaplastic astrocytoma	0-14 yr	203	58.7	(51.3-65.4)	39.7	(32.6-46.8)	30.4	(23.6-37.3)	25.9	(19.3-33.0)
	0-19 yr	273	62.9	(56.6-68.5)	41.9	(35.7-48.0)	31.0	(25.1-37.1)	26.5	(20.6-32.8)
	20-44 yr	1,127	86.4	(84.3-88.4)	71.5	(68.6-74.2)	48.9	(45.5-52.3)	34.5	(30.6-38.4)
	45-54 yr	617	70.0	(66.4-73.8)	47.7	(43.5-51.9)	29.3	(25.2-33.5)	17.6	(13.4-22.4)
	55-64 yr	586	48.5	(44.7-53.0)	25.1	(21.4-28.9)	10.4	(7.6-13.7)	4.4	(1.8-8.8)
	65-74 yr	489	30.8	(27.2-35.8)	13.5	(10.4-17.0)	5.3	(3.2-8.1)	–	–
	75+ yr	380	15.0	(12.3-20.2)	6.4	(3.9-9.7)	0.6	(0.1-3.2)	–	–
Glioblastoma	0-14 yr	246	50.9	(44.2-57.2)	29.1	(23.1-35.4)	22.2	(16.6-28.4)	15.2	(9.7-21.8)
	0-19 yr	357	57.2	(51.7-62.3)	32.5	(27.3-37.8)	19.2	(14.7-24.2)	12.6	(8.3-17.9)
	20-44 yr	2,763	66.5	(64.7-68.3)	35.7	(33.8-37.6)	16.9	(15.3-18.6)	9.9	(8.3-11.6)
	45-54 yr	5,022	52.7	(51.2-54.1)	20.8	(19.6-22)	5.9	(5.1-6.8)	2.7	(1.9-3.6)
	55-64 yr	7,311	40.7	(39.6-41.9)	14.2	(13.3-15.1)	3.8	(3.3-4.4)	1.2	(0.6-2.2)
	65-74 yr	6,908	23.7	(22.6-24.7)	7.2	(6.5-7.9)	1.7	(1.3-2.2)	0.5	(0.2-1.1)
	75+ yr	5,851	9.2	(8.4-10.0)	2.6	(2.2-3.1)	0.8	(0.5-1.2)	–	–
Oligodendroglioma	0-14 yr	146	95.8	(90.9-98.1)	95.1	(89.9-97.6)	92.7	(86.7-96.0)	90.1	(82.4-94.6)
	0-19 yr	251	96.8	(93.6-98.4)	94.6	(90.8-96.9)	92.2	(87.7-95.1)	90.1	(84.6-93.7)
	20-44 yr	1,655	98.1	(97.3-98.7)	95.5	(94.3-96.4)	85.3	(83.2-87.1)	66.4	(63.1-69.6)
	45-54 yr	707	94.1	(91.9-95.7)	89.2	(86.4-91.4)	78.5	(74.7-81.8)	61.1	(55.4-66.4)
	55-64 yr	367	87.3	(83.1-90.5)	78.2	(73.1-82.4)	63.9	(57.6-69.5)	46.7	(38.7-54.3)
	65-74 yr	159	77.0	(69.0-83.1)	68.1	(59.3-75.4)	48.6	(38.8-57.6)	34.5	(22.2-47.1)
	75+ yr	87	58.2	(46.2-68.4)	46.3	(34.1-57.6)	35.7	(22.4-49.3)	–	–
Anaplastic oligodendroglioma	0-14 yr	–	–	–	–	–	–	–	–	–
Anaplastic oligodendroglioma	0-19 yr	33	84.5	(66.5-93.2)	62.3	(43.2-76.6)	–	–	–	–
	20-44 yr	509	93.1	(90.5-95.0)	82.8	(79.0-85.9)	66.5	(61.7-70.9)	49.2	(42.7-55.4)
	45-54 yr	301	84.5	(79.8-88.3)	71.2	(65.4-76.3)	54.5	(47.9-60.7)	42.0	(34.4-49.4)
	55-64 yr	242	74.5	(68.2-79.7)	59.5	(52.6-65.8)	38.3	(31.1-45.5)	25.8	(17.9-34.4)
	65-74 yr	123	49.1	(39.6-57.9)	34.2	(25.4-43.1)	16.2	(9.5-24.6)	8.2	(2.2-19.6)
	75+ yr	49	33.3	(20.0-47.1)	–	–	–	–	–	–
Ependymal tumors	0-14 yr	602	93.6	(91.3-95.4)	86.0	(82.8-88.7)	72.2	(67.9-76.1)	62.8	(57.5-67.7)
	0-19 yr	716	94.0	(91.9-95.5)	86.9	(84.1-89.3)	74.7	(70.9-78.1)	64.9	(60.0-69.3)
	20-44 yr	813	96.4	(94.9-97.5)	95.0	(93.1-96.4)	91.4	(88.9-93.4)	89.0	(85.7-91.6)
	45-54 yr	451	93.9	(91.1-95.9)	91.2	(87.9-93.7)	85.7	(81.2-89.1)	84.3	(79.5-88.1)
	55-64 yr	312	92.8	(88.9-95.3)	88.6	(83.9-92.0)	84.9	(78.9-89.3)	84.9	(78.9-89.3)
	65-74 yr	149	89.3	(82.4-93.7)	79.4	(70.6-85.8)	76.6	(67.0-83.8)	70.9	(56.5-81.3)
	75+ yr	76	76.7	(64.5-85.2)	72.5	(58.2-82.6)	67.8	(51.3-79.7)	36.0	(12.7-60.3)
Oligoastrocytic tumors	0-14 yr	77	94.6	(86.1-98.0)	86.5	(75.5-92.8)	78.7	(65.6-87.3)	72.5	(56.9-83.3)
	0-19 yr	126	93.4	(87.1-96.7)	86.8	(79.0-91.9)	81.2	(72.1-87.6)	76.1	(65.0-84.1)
	20-44 yr	975	95.8	(94.3-97.0)	89.4	(87.1-91.2)	71.2	(67.7-74.5)	55.8	(50.9-60.4)
	45-54 yr	356	86.8	(82.7-90.0)	74.7	(69.5-79.2)	59.3	(53.0-65.0)	40.8	(32.2-49.2)
	55-64 yr	203	70.7	(63.5-76.7)	46.9	(39.1-54.3)	29.7	(22.1-37.7)	22.9	(14.6-32.3)
	65-74 yr	111	62.6	(52.2-71.4)	40.9	(30.6-50.9)	27.9	(18.2-38.4)	19.3	(7.7-34.8)
	75+ yr	–	–	–	–	–	–	–	–	–
Glioma malignant, NOS	0-14 yr	1,322	73.6	(71.0-75.9)	60.5	(57.6-63.2)	56.9	(54-59.7)	55.6	(52.6-58.5)
	0-19 yr	1,463	75.1	(72.8-77.3)	62.6	(59.9-65.1)	58.4	(55.6-61.0)	57.0	(54.2-59.8)
	20-44 yr	779	87.0	(84.3-89.2)	77.3	(74.0-80.2)	64.4	(60.4-68.1)	48.7	(43.5-53.6)
	45-54 yr	405	70.5	(65.6-74.9)	56.9	(51.7-61.9)	47.1	(41.5-52.4)	38.7	(32-45.5)
	55-64 yr	349	47.9	(42.3-53.2)	35.6	(30.2-40.9)	25.1	(19.9-30.6)	22.6	(16.8-29.1)
	65-74 yr	363	33.2	(28.3-38.3)	20.5	(16.3-25.1)	14.5	(10.6-19.0)	11.7	(7.9-16.4)
	75+ yr	655	15.2	(12.5-18.3)	10.8	(8.3-13.6)	6.9	(4.4-10.2)	5.5	(2.5-10.4)
Neuronal and mixed neuronal-glial tumors	0-14 yr	39	97.1	(80.9-99.6)	90.6	(73.3-96.9)	87.2	(69.2-95.1)	87.2	(69.2-95.1)
	0-19 yr	62	96.3	(85.8-99.1)	86.3	(73.2-93.3)	84.1	(70.5-91.8)	72.4	(41.2-88.9)
	20-44 yr	132	94.4	(88.3-97.3)	91.0	(84.0-95.0)	78.3	(68.7-85.3)	56.9	(41.8-69.4)
	45-54 yr	117	92.4	(85.5-96.1)	88.9	(80.9-93.6)	77.9	(67.5-85.4)	69.2	(53.8-80.3)
	55-64 yr	84	88.5	(78.8-93.9)	72.1	(59.9-81.2)	59.2	(45.6-70.4)	44.2	(27.5-59.6)
	65-74 yr	42	78.8	(61.5-89.0)	74.9	(56.3-86.4)	73.1	(53.5-85.5)	49.0	(21.4-71.9)
	75+ yr	32	70.9	(50.1-84.3)	56.1	(34.2-73.2)	56.1	(34.2-73.2)	–	–
Embryonal tumors	0-14 yr	1,781	79.9	(77.9-81.7)	70.3	(68.0-72.5)	62.1	(59.6-64.5)	55.5	(52.7-58.3)
	0-19 yr	1,955	80.9	(79.1-82.6)	71.0	(68.9-73.0)	61.9	(59.5-64.2)	55.8	(53.1-58.4)
	20-44 yr	557	86.3	(83.0-88.9)	79.1	(75.3-82.4)	64.6	(60.0-68.9)	56.0	(50.7-61.1)
	45-54 yr	72	78.8	(67.2-86.8)	66.3	(53.3-76.4)	51.6	(37.2-64.3)	31.0	(14.9-48.6)
	55-64 yr	45	67.6	(51.1-79.6)	48.8	(32.2-63.5)	–	–	–	–
	65-74 yr	–	–	–	–	–	–	–	–	–
	75+ yr	–	–	–	–	–	–	–	–	–
Meningioma	0-14 yr	–	–	–	–	–	–	–	–	–
	0-19 yr	–	–	–	–	–	–	–	–	–
	20-44 yr	150	96.7	(91.9-98.7)	96.0	(90.9-98.3)	91.6	(84.7-95.4)	85.2	(76.2-91.0)
	45-54 yr	182	92.4	(87.3-95.6)	86.2	(79.9-90.7)	76.9	(69.1-82.9)	72.0	(62.4-79.6)
	55-64 yr	252	87.4	(82.4-91.1)	78.3	(72.2-8.32)	66.9	(59.6-73.1)	48.9	(38.6-58.5)
	65-74 yr	227	83.0	(76.9-87.6)	72.7	(65.6-78.6)	55.6	(47.1-63.3)	52.0	(42.7-60.5)
	75+ yr	276	63.5	(56.8-69.5)	54.3	(46.9-61.2)	45.9	(37.0-54.3)	29.1	(16.1-43.5)
Lymphoma	0-14 yr	41	87.6	(72.6-94.6)	84.7	(68.9-92.8)	78.2	(60.7-88.6)	72.7	(52.3-85.5)
	0-19 yr	67	83.2	(71.6-90.3)	77.9	(65.4-86.3)	74.0	(60.8-83.3)	66.5	(49.9-78.6)
	20-44 yr	1,054	40.1	(37.1-43.1)	34.3	(31.4-37.3)	29.0	(26.1-31.9)	23.0	(19.8-26.2)
	45-54 yr	724	56.5	(52.7-60.1)	48.2	(44.4-51.9)	38.2	(34.3-42.1)	30.2	(25.6-35.0)
	55-64 yr	855	60.1	(56.6-63.4)	49.4	(45.8-52.9)	37.0	(33.2-40.7)	27.4	(23.0-31.8)
	65-74 yr	983	47.5	(44.2-50.7)	37.5	(34.2-40.7)	23.5	(20.3-26.9)	12.9	(9.0-17.4)
	75+ yr	817	33.6	(30.2-37.0)	23.2	(20.0-26.5)	13.4	(10.3-16.8)	9.7	(6.5-13.6)
Total: All Brain and Other Nervous System^∥	0-14 yr	7,935	85.2	(84.4-86.0)	78.0	(77.0-78.9)	72.3	(71.2-73.3)	68.2	(66.9-69.4)
	0-19 yr	9,690	86.4	(85.7-87.1)	79.1	(78.3-80.0)	73.0	(72.0-74.0)	69.0	(67.9-70.1)
	20-44 yr	14,100	83.3	(82.7-83.9)	72.2	(71.4-72.9)	58.1	(57.1-59.0)	46.0	(44.9-47.1)
	45-54 yr	10,400	65.7	(64.8-66.7)	44.9	(43.9-46.0)	31.8	(30.8-32.8)	24.9	(23.8-26.1)
	55-64 yr	11,856	49.9	(49.0-50.9)	28.2	(27.3-29.1)	17.4	(16.6-18.2)	12.9	(12.0-13.9)
	65-74 yr	10,694	32.1	(31.1-33.0)	17.3	(16.5-18.1)	10.2	(9.5-10.9)	7.2	(6.3-8.1)
	75+ yr	10,090	16.0	(15.2-16.8)	9.1	(8.5-9.8)	5.8	(5.2-6.5)	3.7	(2.9-4.6)

Age Group	2000 U.S.	Age Group	2000 U.S.	Age Group	2000 U.S.
0-4	18,986,520	45-49	19,805,793	Total	274,633,642
5-9	19,919,840	50-54	17,224,359
10-14	20,056,779	55-59	13,307,234
15-19	19,819,518	60-64	10,654,272
20-24	18,257,225	65-69	9,409,940
25-29	17,722,067	70-74	8,725,574
30-34	19,511,370	75-79	7,414,559
35-39	22,179,956	80-84	4,900,234
40-44	22,479,229	85 +	4,259,173

Male
Age Group	White	Black	AIAN	API	Total
0-4	7,704,319	1,666,608	177,834	568,767	10,117,528
5-9	7,673,938	1,631,064	170,615	533,167	10,008,783
10-14	8,005,004	1,745,921	177,066	527,798	10,455,790
15-19	8,489,499	1,884,377	192,320	565,381	11,131,576
20-24	8,293,773	1,608,581	177,773	625,174	10,705,301
25-29	8,023,850	1,408,351	159,655	663,595	10,255,451
30-34	7,531,629	1,275,314	143,303	654,541	9,604,788
35-39	8,029,489	1,310,118	137,549	650,234	10,127,390
40-44	8,426,157	1,345,580	134,151	576,813	10,482,701
45-49	9,003,812	1,365,169	129,963	532,774	11,031,718
50-54	8,549,064	1,225,188	111,275	471,156	10,356,683
55-59	7,560,394	977,094	86,060	392,125	9,015,673
60-64	6,186,395	687,511	61,798	294,104	7,229,809
65-69	4,592,714	484,412	41,089	214,426	5,332,640
70-74	3,473,536	349,867	26,783	155,753	4,005,940
75-79	2,761,388	236,193	16,789	104,713	3,119,083
80-84	1,985,600	145,665	9,779	65,845	2,206,888
85+	1,476,134	100,958	6,326	48,308	1,631,727
Total	117,766,696	19,447,970	1,960,128	7,644,675	146,819,470

Female
Age Group	White	Black	AIAN	API	Total

0-4	7,350,092	1,612,527	172,967	548,505	9,684,091
5-9	7,308,715	1,578,664	165,717	531,102	9,584,198
10-14	7,600,173	1,686,196	173,511	512,799	9,972,679
15-19	8,000,625	1,825,637	181,373	536,822	10,544,458
20-24	7,808,263	1,628,358	160,674	611,859	10,209,155
25-29	7,728,520	1,540,244	148,493	721,841	10,139,098
30-34	7,270,847	1,429,718	138,212	720,911	9,559,688
35-39	7,858,362	1,479,055	135,769	718,943	10,192,129
40-44	8,337,261	1,512,502	134,062	640,932	10,624,757
45-49	9,048,839	1,539,915	133,962	599,266	11,321,981
50-54	8,730,875	1,402,193	117,780	547,031	10,797,879
55-59	7,879,048	1,158,988	92,067	471,140	9,601,243
60-64	6,582,943	848,210	66,024	352,250	7,849,427
65-69	5,091,513	635,157	45,435	253,187	6,025,292
70-74	4,081,538	495,032	32,453	192,945	4,801,968
75-79	3,568,561	382,175	22,629	146,435	4,119,801
80-84	3,010,168	278,441	14,936	100,439	3,403,983
85+	3,109,806	264,165	12,645	81,526	3,468,142
Total	120,366,150	21,297,175	1,948,709	8,287,935	151,899,969

Male
Age Group	Hispanic	Non-Hispanic	Total
0-4	2,524,048	7,593,480	10,117,528
5-9	2,254,938	7,753,845	10,008,783
10-14	2,197,898	8,257,892	10,455,790
15-19	2,211,025	8,920,551	11,131,576
20-24	2,207,996	8,497,305	10,705,301
25-29	2,217,253	8,038,198	10,255,451
30-34	2,052,774	7,552,013	9,604,788
35-39	1,884,223	8,243,166	10,127,390
40-44	1,668,156	8,814,545	10,482,701
45-49	1,408,246	9,623,472	11,031,718
50-54	1,092,289	9,264,394	10,356,683
55-59	806,238	8,209,435	9,015,673
60-64	566,014	6,663,795	7,229,809
65-69	389,476	4,943,164	5,332,640
70-74	281,654	3,724,286	4,005,940
75-79	200,116	2,918,967	3,119,083
80-84	126,028	2,080,860	2,206,888
85+	82,369	1,549,358	1,631,727
Total	24,170,742	122,648,728	146,819,470

Female

Age Group	Hispanic	Non-Hispanic	Total

0-4	2,423,748	7,260,344	9,684,091
5-9	2,162,117	7,422,081	9,584,198
10-14	2,105,032	7,867,647	9,972,679
15-19	2,040,089	8,504,368	10,544,458
20-24	1,905,160	8,303,994	10,209,155
25-29	1,954,478	8,184,620	10,139,098
30-34	1,889,179	7,670,509	9,559,688
35-39	1,785,003	8,407,125	10,192,129
40-44	1,591,464	9,033,293	10,624,757
45-49	1,382,800	9,939,181	11,321,981
50-54	1,116,037	9,681,842	10,797,879
55-59	866,689	8,734,554	9,601,243
60-64	642,980	7,206,446	7,849,427
65-69	472,440	5,552,853	6,025,292
70-74	366,208	4,435,760	4,801,968
75-79	280,775	3,839,026	4,119,801
80-84	193,730	3,210,253	3,403,983
85+	157,184	3,310,958	3,468,142
Total	23,335,113	128,564,856	151,899,969

Histology	ICD-O-3^† Histology Code
II Lymphomas and reticuloendothelial neoplasms
II(a) Hodgkin lymphomas	9650-9655, 9659, 9661-9665, 9667
II(b) Non-Hodgkin lymphomas (except Burkitt's lymphoma)	9591, 9670, 9671, 9673, 9675, 9678-9680, 9684, 9689-9691, 9695, 9698-9702, 9705, 9708, 9709, 9714, 9716-9719, 9727-9729, 9731-9734, 9760-9762, 9764-9769, 9970
II(c) Burkitt lymphoma	9687
II(d) Miscellaneous lymphoreticular neoplasms	9740-9742, 9750, 9754-9758
II(e) Unspecified lymphomas	9590, 9596
III CNS and miscellaneous intracranial and intraspinal neoplasms
III(a) Ependymomas and choroid plexus tumor	9383, 9390-9394
III(b) Astrocytomas	9380 (Only Site C723), 9384, 9400-9411, 9420, 9421-9424, 9440-9442
III(c) Intracranial and intraspinal embryonal tumors	9470-9474, 9480, 9501-9504 (Only Site C700-C729), 9508
III(d) Other gliomas	9380 (Only Sites C700-C722, C724-C729, C751, C753), 9381, 9382, 9430, 9444, 9450, 9451, 9460
III(e) Other specified intracranial/intraspinal neoplasms	8270-8281, 8300, 9350-9352, 9360-9362, 9412, 9413, 9492, 9493, 9505-9507, 9530-9539, 9582
III(f) Unspecified intracranial and intraspinal neoplasms	8000-8005
IV Neuroblastoma and other peripheral nervous cell tumors
IV(a) Neuroblastoma and ganglioneuroblastoma	9490, 9500
IV(b) Other peripheral nervous cell tumors	8680-8683, 8690-8693, 8700, 9520-9523, 9501-9504 (Only Site C000-C699, C739-C768)
IX Soft tissue and other extraosseous sarcomas
IX(a) Rhabdomyosarcomas	8900-8905, 8910, 8912, 8920, 8991
IX(b) Fibrosarcomas, peripheral nerve & other fibrous	8810, 8811, 8813-8815, 8821, 8823, 8834-8835 (All Prior Only On Sites C000-C399, C440-C768, C809), 8820, 8822, 8824-8827, 9150, 9160, 9491, 9540-9571, 9580
IX(c) Kaposi sarcoma	9140
IX(d) Other specified soft tissue sarcomas	8587, 8710-8713, 8806, 8830 (Only Sites C000-C399, C440-C768, C809), 8831-8833, 8836, 8840-8842, 8850-8858, 8860-8862, 8870, 8880, 8881, 8890-8898, 8921, 8963 (Only Sites C000-C639, C659-C699, C739-C768, C809), 8982, 8990, 9040-9044, 9120-9125, 9130-9133, 9135, 9136, 9141, 9142, 9161, 9170-9175, 9180 (Only Sites C490-C499), 9210 (Only Sites C490-C499), 9220 (Only Sites C490-C499), 9240 (Only Sites C490-C499) 9231, 9251, 9252, 9260 (C000-C399, C470-C759), 9364 (Only Sites C000-C399, C470-C639, C659-C699, C739-C768, C809), 9365 (Only Sites C000-C399, C470-C639, C659-C768, C809), 9373, 9581
IX(e) Unspecified soft tissue sarcomas	8800-8805
XII Other and unspecified malignant neoplasms
XII(a) Other specified malignant tumors	8930-8936, 8950, 8951, 8971-8981, 9050-9055, 9110, 9363 (Only Sites C000-C399, C470-C759)
XII(b) Other unspecified malignant tumors	8000-8005

PERMALINK

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

Quinn T Ostrom

Haley Gittleman

Paul Farah

Annie Ondracek

Yanwen Chen

Yingli Wolinsky

Nancy E Stroup

Carol Kruchko

Jill S Barnholtz-Sloan

Introduction

Background

Technical Notes

Data Collection

Fig. 1.

Definitions

Measures in Surveillance Epidemiology

Classification by Behavior and Histology

Table 1.

Table 1a.

Table 1b.

Anatomic Location of Tumor Sites

Measurement Methods

Brain Tumor Definition Differences

Estimation of Expected Numbers of Brain and CNS Tumors in 2013 and 2014

Estimation of Mortality Rates for Underlying Cause from Brain and CNS Tumors

Estimation of Survival Rates

Data Interpretation

Results

Primary Brain and CNS Tumors: Distributions and Incidence by Gender, Race, Hispanic Ethnicity, Age Group, Cancer Registry, and Behavior

Table 2.

Table 3.

Table 4.

Table 5.

Table 6.

Table 7.

Table 8.

Table 9.

Overall Incidence Rates

Fig. 2.

Overall Incidence Rates by Year

Fig. 3.

Incidence Rates by Central Cancer Registry, Age, and Behavior

Table 10.

Fig. 4.

Primary Brain and CNS Tumors: Incidence by Site, Histology, Age, Gender, Race, and Hispanic Ethnicity

Distribution of Tumors by Site and Histology

Fig. 5.

Fig. 6.

Fig. 7.

Fig. 8.

Incidence of Spinal Cord Tumors

Fig. 9.

Distribution of Tumors by Site and Histology in Young Adults (Ages 20-34 Years)

Fig. 10.

Incidence Rates by Site and Gender

Table 11.

Incidence Rates by Major Histology Groupings and Specific Histologies

Table 12.

Incidence Rates by Behavior and Histology

Median Age at Diagnosis

Incidence Rates by Gender and Histology

Fig. 11.

Incidence Rates by Race and Histology

Fig. 12.

Incidence Rates by Hispanic Ethnicity and Histology

Incidence Rates by Age and Histology

Table 13.

Fig. 13.

Table 14.

Estimated Numbers of Expected Cases of All Primary Brain and CNS Tumors by State

Table 15.

Childhood Primary Brain and CNS Tumors: Incidence by Site, Histology, Gender, and Age

Childhood Brain Tumors

Distribution of Tumors by Site and Histology

Fig. 14.

Fig. 15.

Fig. 16.

Table 19.